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Abstract 
Artificial metalloenzymes are designed to gather advantages of both homogeneous catalysts 
and enzymes. The biotin-(strept)avidin technology insures the incorporation of an active 
catalyst in a proteinic scaffold which provides a chiral environment. The combination of 
these two parts provides efficient artificial metalloenzymes applied in various asymmetric 
reactions such as hydrogenation, transfer hydrogenation, allylic alkylation, etc… 
In this work, the properties of (strept)avidin were used  to explore new challenges for 
artificial metalloenzymes. 
Artificial hydrogenases were used as model reaction to demonstrate that artificial 
metalloenzymes can be more than a concept. With this goal in mind, the loading of the 
artificial hydogenase was reduced to 0.1% and the concentration of substrate increased to 60 
mM with very small erosion of activity and selectivity. The scale of the reaction was 
increased 15 times without any impact on conversion and ee. Recycling of the artificial 
hydrogenase was investigated by immobilizing streptavidin using biotin sepharose. The 
resulting artificial metalloenzymes could be used twice without any loss of activity. 
Lyophilisation of the artificial hydrogenase allows a convenient storage of the artificial 
hydrogenase. 
The versatibilty of the biotin-streptavidin technology was exploited to create and optimize 
artificial allylic alkylases. The thermostability of streptavidin and its high tolerance towards 
organic solvents resulted good conversions and ee values up to 97%. 
 
The thermostability of streptavidin was further investigated as a potential rapid purification 
strategy towards screening heat-treated cell-free extracts.  
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With the aim of selective modification of tyrosine-residues, the potential of the artificial 
allylic alkylases was extended towards the use of phenol as nucleophile. The reaction was 
optimized to operate under physiological conditions. Detailed investigations of the reaction 
suggested self-alyllation of the tyrosine residues of the artificial metalloenzyme. 
Artificial ligases were developed by incorporation of a biotinylated Hoveyda-Grubbs 2
nd
 
generation catalyst in (strept)avidin. The optimization of the artificial metalloenzyme gave 
good conversions for ring closing metathesis of diallyltosylamine under acidic pH and high 
salt concentration. 
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I. Introduction   
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1.1. General 
 
The distinction between chemistry and biology is ever increasingly becoming smaller and 
smaller. Advances in the fields of chemistry and biology allow the understanding of various 
processes involved in life. Bioinorganic chemistry is an example of a domain at the interface 
between chemistry and biology. Garner defined bioinorganic chemistry as an 
interdisciplinary field of science which draws on the strengths of the disciplines of inorganic 
chemistry and biological sciences and requires the application of advanced physical and 
theoretical methodologies 
[1]
. The core of bioinorganic chemistry has focused on the study of 
metal sites in biological processes. 
The nature of the metal involved is linked to its function in the organism. Group I and II 
metals such as sodium, potassium or calcium are found in charge regulation processes or as 
structural elements 
[2]
. The function of transition metals can be varied. Metals existing in a 
single oxidation state can function either as structural elements or lewis acids. As an example, 
zinc fingers are protein domains in which zinc chelates residues (cysteines, histidines,...) to 
contribute to the stability of the protein. Elements that exist in different oxidation states like 
iron or copper have roles in electron transfer, oxygen transport or redox chemistry. Catalytic 
activity of metalloenzymes is most often ensured by transition metals, for example, cobalt is 
found in vitamin B12, an essential cofactor of enzymes involved in protection of the nervous 
system or the synthesis of methionine (Figure 1) 
[3, 4]
. 
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Figure 1. Coenzyme B12. 
 
1.2.  Metalloenzymes 
 
Metalloenzymes are biological catalysts constituted of a proteinic part into which a metal is 
incorporated, providing the catalytic activity 
[5]
.  
 
1.2.1. Definition of catalyst. 
 
A catalyst can be defined as a species that increases the rate of a chemical reaction. The 
catalyst is regenerated during the reaction and that allows using a small quantity of this 
substance 
[6]
. 
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Figure 2. Energetic diagram of a catalyzed reaction 
 
The thermodynamics and the equilibrium of the overall reaction are not affected by the 
catalyst; however, the catalyst changes the Gibbs-free energy of the transition state (Figure 
2). It reduces the highest energy barrier by stabilizing the transition state observed in the 
uncatalyzed reaction.  
 
1.2.2. Examples of efficiency of metalloenzymes. 
 
1.2.2.1. Nitrogenases. 
 
Nitrogenases are metalloenzymes able to generate ammonia from N2. These metalloenzymes 
are found in some prokaryotic organisms. Fixed nitrogen is indispensable to life as it is 
required for the biosynthesis of amino acids and nucleic acids 
[7-9]
. 
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Figure 3.  Nitrogenase. (PDB: 1N2C) 
 
This enzyme consists of two different subunits, the Fe-protein and the MoFe-protein (Figure 
3). The MoFe-protein contains two clusters: a Fe-S cluster named the P-cluster and a second 
cluster containing iron, sulfur and another metal such as molybdenum, vanadium or iron. In 
most of the cases, the cofactor contains molybdenum and is called FeMoco. 
This MoFe-protein is associated with a Fe-protein which is bridged to the MoFe-protein by 
an additional Ferredoxin Fe-S cluster (Figure 4). 
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Figure 4. Representation of the metalloclusters in nitrogenase. (Adapted from PDB files 
1M1N and 2NIP). Iron is represented in orange, sulfur in yellow, nitrogen in blue, 
molybdenium in sky blue, oxygen in red and carbon in grey. 
 
The mechanism of nitrogen reduction is not fully elucidated but several points are widely 
accepted (Scheme 1) 
[10-12]
. At the first step, the Fe-protein and the MoFe-protein associate to 
form the complex triggering an electron transfer from the Ferredoxin to the P-cluster and then 
further to the FeMoco. In the same time, two ATP molecules which were bound to the Fe-
protein are hydrolyzed to ADP and phosphate salts. At this point, the Fe-protein and the 
MoFe-protein dissociate and the cycle starts again. During this cycle, one electron is 
transferred to the active site. In order to reduce one N2 molecule, this cycle has to run eight 
times. 
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Scheme 1. Mechanism of reduction of N2 with nitrogenase 
 
 
Nitrogenases illustrate the cooperation between inorganic complexes and proteinic scaffolds. 
The interactions of the different clusters with amino acid residues of the proteinic scaffold, 
for example, cysteines allow them to be so efficient. Many attempts to isolate the FeMoco 
have been made. However, it has not yet been possible to catalyze ammonia synthesis in 
comparable yields with the isolated FeMoco or a synthetic analogue 
[13-17]
. Until now, the 
Haber-Bosch process is the unique way to produce ammonia industrially from N2 and H2 in 
presence of an iron catalyst (Scheme 2) 
[18, 19]
. 
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Scheme 2. Haber-Bosch process. 
 
However, this process requires high temperatures and pressures. This is due to the fact that in 
the process, atomic nitrogen binds to the surface of the catalyst. Although the equilibrium is 
shifted towards the reactants, this phenomenon can be avoided by increasing the temperature. 
Additionally, the pressure must be increased in order to move the equilibrium in favor of 
product formation. 
 
1.2.2.2.  Cytochrome P 450. 
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Cytochrome P450s are another illustration of the importance of the interactions between a 
proteinic scaffold and the active metal 
[20-23]
. Cytochrome P450 transfers one atom of oxygen 
from molecular oxygen to a substrate in the presence of a reducing agent.  
Cytochrome P450s are metalloporphyrins consisting of an iron porphyrin with a cysteine 
acting as an axial ligand. The other axial position is used for the activation site of O2. 
 
Figure 5. Comparaison between cythochrome P450 (left) and hemoglobyn (right). (PDB 
: 1JPZ and 3AQ5) 
 
The amino acid acting as an axial ligand is the unique difference in the first coordination 
sphere of iron between cytochrome P450 and others metalloproteins such as hemoglobin or 
myoglobin (Figure 5). In the case of hemoglobin or myoglobin, the position is occupied by a 
histidine residue. Hemoglobin and myoglobin ensure the transport of dioxygen in blood by 
forming a reversible Fe-O-O complex. The difference in activity of hemoglobin vs. 
cytochrome P450 is explained by the effect of the ligand in trans of the fixation site of 
molecular oxygen 
[24]
, as well as subtle differences in the second coordination sphere. These 
latter are particularly hard to control in small bio-inorganic model compounds. This may well 
be one of the reasons why such model compounds rarely rival with the versatility of 
metalloenzymes. 
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1.3. Artificial metalloenzymes. 
 
1.3.1. Concept of artificial metalloenzymes. 
 
Many reactions can be improved in the presence of a catalyst or an enzyme (Table 1) 
[25]
. In 
most cases, conditions required with enzymes are milder than those required with either 
homogeneous or heterogeneous catalysts. Each system however has its own advantages and 
disadvantages (Table 2).  
 
Table 1. Comparison of chemical and biological systems. 
 
Reactions Chemical system Biological system 
Methane 
hydroxylation 
 
CH4 + H2O  CO + 3 H2 
(Ni catalyst, 700-900°C, 1–25 bar) 
CO + 2 H2   CH3OH 
(Cu/Zn catalyst, 250-280°C, 70-
110bar) 
 
CH4 + O2 + NADH + H
+
   CH3OH + H2O + NAD
+
 
(methane monooxygenase) 
CO oxidation CO + H2O   CO2 + H2 
(Fe/Cu catalyst, >200°C) 
 
CO + H2O   CO2 + 2 H
+
 + 2e¯ 
(CO dehydrogenase) 
 
CO insertion CH3OH + CO   CH3COOH 
[Rh(I)I2(CO2)]¯, 120°C, 30 atm 
 
CH3−[M] + CO + HS−CoA   CH3(CO)−S−CoA + H
+
 + [M]¯
 [a]
 
(acetyl-CoA synthase) 
[a]CH3−[M] is a corrinoid-iron-sulfur protein that acts in the reaction as a methyl group donor; HS-CoA is the 
coenzyme. 
 
 For example, transition metal catalysts are cheaper and easier to synthesize. They are also 
well characterized and more resistant to harsh conditions of temperature and pressure. On the 
other hand, enzymes are very selective and have a higher tolerance to other functionalities. In 
addition, the environment around the active site ensures a high stability and often enables 
high turnover numbers. Finally, enzymes are active under physiological conditions. 
 
21 
 
Table 2. Comparison between homogeneous and enzymatic catalysis. 
 
Parameters Homogeneous catalysis Enzymatic catalysis 
Substrate scope Large Limited 
Enantiomers 2 enantiomers 1 enantiomer 
Tolerance to organic solvents Excellent Limited 
Substrate concentration High Low to moderate 
TON/TOF Average High 
Optimization Chemical synthesis Genetic 
Repertoire of reaction 
 
Large Restricted 
Second sphere coordination 
 
Ill-defined Well-defined 
Reactions condition High temperature and 
pressure 
Room temperature and 
atmospheric pressure 
Environmental impact Hazardous Friendly 
 
Artificial metalloenzymes are aimed at combining the advantages of transition metal 
catalyzed reactions with those of enzymes 
[26-28]
. This results from the incorporation of a 
metal complex with a catalytic activity in a macromolecular host which provides a defined 
environment around the metal. 
 
1.3.2. Design of artificial metalloenzymes. 
 
 The three key parameters in the design of an artificial metalloenzyme are the transition metal 
catalyst, the biomolecular scaffold and the mode of attachment of the transition metal catalyst 
to the biomolecular scaffold. 
 
1.3.2.1. Transition metal catalyst. 
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The transition metal is responsible for the activity of the artificial metalloenzyme. Recent 
advances in the field of transition metal catalyzed reactions considerably enlarge the reaction 
scope where such a system can be applicable 
[29]
. One critical limitation of organometallic 
catalyst is water compatibility. Another point that should be taken into consideration is the 
compatibility of the reaction conditions (temperature, pressure,…) or reagents (surfactants, 
oxidizing agents,…) with the stability of the biomolecular scaffold. 
 
1.3.2.2. Biomolecular scaffold. 
 
The biomolecular scaffold provides the second coordination sphere around the metal. Most 
often, the biomolecular scaffold is selected based on the presence of an existing active site 
that can be modified in order to incorporate a new functionality. 
Kaiser, one of the pioneer in this field, developped a Cu(II) carboxypeptidase that catalyses 
the oxidation of ascorbic acid 
[30]
. 
Ueno, Watanabe and co workers described the in situ synthesis of a palladium cluster 
incorporated in apo-ferritin, an iron storage protein, and performed size-selective olefin 
hydrogenation 
[31-33]
. 
An alternative is to use a biomolecular scaffold where the active site is not present but 
entirely created by the introduction of new functionality. This strategy offers the advantage of 
enlarging the scope of biomolecular scaffolds 
[34]
. 
Distefano used iodoacetamido-1,10-phenanthroline to modify a unique cysteine residue in  
adipocyte lipid binding protein (ALBP) to produce the conjugate ALBP-Phen. ALBP-Phen-
Cu(II) catalyzed the enantioselective hydrolysis of several unactivated amino acid esters 
[35-
37]
. 
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Mahy and coworkers presented new anionic metalloporphyrin–estradiol conjugate which was 
associated to a monoclonal anti-estradiol antibody 7A3, to generate new artificial 
metalloenzymes used in oxidation reactions 
[38-40]
. 
A new approach was introduced by using DNA or peptides as scaffold for the creation of 
artificial metalloenzymes 
[41, 42]
. 
Franklin and coworkers designed a chimeric Cu-peptide for DNA recognition 
[43-47]
. 
Komiyama created an artificial restriction DNA cutter using two oligonucleotides bearing a 
monophosphate group combined to a Ce(IV)/EDTA complex 
[48-51]
. In the same spirit, 
Krämer presented a peptide nucleic acid conjugated with a Zr(IV) complex for DNA scission 
[52]
. 
Roelfes and Feringa used DNA as a scaffold for inducing selectivity and rate acceleration in 
several reactions such as Diels-Alder reactions, Michael reactions or Friedel-Crafts reactions 
[53-58]
 . 
  
1.3.2.3. Anchoring strategy. 
 
The anchoring of the transition metal in the biomolecular scaffold is a key issue as random 
localization of the transition metal within the biomolecular scaffold must be avoided. There 
are three strategies for anchoring: covalent, dative and supramolecular (Scheme 3) 
[59]
. 
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Scheme 3. Anchoring strategies for the creation of artificial metalloenzymes. 
 
The covalent anchoring strategy relies on the creation of a covalent bond between one or 
several amino acids of the biomolecular scaffold (for example, cysteines) and a ligand of the 
transition metal catalyst. Many papers have reported the covalent anchoring of the cofactor to 
biomolecular scaffolds. As an example, Lu reported the anchoring of a Mn salen complex to 
myoglobin by the creation of two new covalent bonds between the ligand and the protein 
(Scheme 4) 
[60]
.  
Kamer and co workers reported covalent anchoring of various phosphine ligands on 
photoactive yellow protein 
[61-63]
. 
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Scheme 4. Example of covalent anchoring: synthesis of phosphine-protein conjugates 
developed by Kamer (left) and double anchoring of Mn-salen on apo-Myoglobin 
developed by Watanabe (right). 
 
In the dative anchoring strategy, one amino acid of the biomolecular acts as a ligand for the 
metal complex. Kokubo et al. demonstrated that a 1:1 complex of an osmate ester and bovine 
serum albumin (BSA) functions as a catalyst in the cis dihydroxylation of alkenes (up to 68% 
ee) 
[64]
. Kazlauskas substituted zinc by rhodium in carbonic anhydrase to yield an artificial 
metalloenzyme for hydrogenation and hydroformylation (Scheme 5) 
[65, 66]
.  
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Using the same principle, Soumillion introduced manganese in carbonic anhydrase for 
selective epoxidation of alkenes 
[67, 68]
.  
 
 
Scheme 5. Artificial metalloenzyme developed by Kazlauskas using dative anchoring. 
 
The supramolecular anchoring strategy relies on weak the interactions between small 
molecules and the biomolecular scaffold. The crucial point of this strategy is the affinity of 
the guest molecule for the host biomolecular scaffold. Harada used the high affinity of 
antibodies for the creation of an artificial hydrogenase 
[69]
. In the same spirit, Keinan 
presented an antibody-metalloporphyrin assembly that catalyzed enantioselective oxidations 
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[70, 71]
. In his early report, Whitesides described the creation of an artificial metalloenzyme 
based on very high affinity of biotin for avidin 
[72]
. 
 
1.4. Artificial metalloenzymes based on the biotin –(strept)avidin technology. 
 
1.4.1. Biotin-(strept)avidin technology. 
 
Avidin is a glycosylated protein that is naturally present in egg white 
[73-75]
.  Streptavidin is 
secreted by Streptomyces bacteria. This protein is expressed in Escherichia coli with 
relatively high yield 
[76]
. In contrast to avidin, streptavidin is not glycosylated. 
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Figure 6. Representation of avidin monomer (top) and streptavidin monomer (bottom) 
with biotin bound. (PDB: 1AVD and 1SWE) 
 
Avidin as well as streptavidin are tetrameric eight stranded -barrel proteins which bind up to 
four biotins with high affinity. They display 31% sequence identity (41% homology) (Figure 
6) 
[77-81]
. 
These proteins are extremely robust and stable at high temperatures 
[76]
, at extreme pH 
[82-84]
  
and high concentrations of denaturating agents 
[83, 85]
.   As an example, avidin does not 
denature with 6M guanidinium at pH 1.5 
[85]
. The robustness of these proteins allows the use 
of these scaffolds for a wide range of applications. 
Biotin-(strept)avidin is often described as  molecular Velcro 
[86, 87]
.  The interaction between 
biotin and (strept)avidin is extremely tight with a Ka = 1.7*10
15
 M
-1
 for avidin and Ka = 
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2.5*10
13
 M
-1
 for streptavidin 
[75]
. These high values ensure a quasi irreversible anchoring of a 
biotinylated compound into the protein pocket as a result of numerous interactions between 
biotin and the protein such as hydrophobic interactions 
[77, 79, 88-92]
, Van der Waals interactions 
and hydrogen bonding (Figure 7) 
[88, 93-98]
. All applications of the biotin-(strept)avidin 
technology rely on the fact that the valeric acid side chain of biotin can be derivatized with 
little influence on the remarkable affinity of the biotin-(strept)avidin couple 
[99-110]
. 
 
 
Figure 7. Representation of the interactions biotin-avidin (left) and biotin-streptavidin 
(right) 
 
Since 2003, the Ward group has intensively explored the biotin (Strept)avidin technology for 
the creation of artificial metalloenzymes 
[111-114]
.  
The presence of the biomolecular scaffold offers an additional advantage for optimization of 
the artificial metalloenzyme (Scheme 6). While chemical optimization can be achieved by 
modifiying the ligand or by introducing a spacer between the biotin anchor and the metal, the 
biomolecular scaffold can be genetically modified in order to influence the environment 
around the metal. By identification of the residues that are near to the active site, saturation 
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mutagenesis allows one to exchange the selected amino acid with the remaining 19 natural 
amino acids.  
 
 
Scheme 6. Chemogenetic optimization of the artificial metalloenzyme. 
 
1.4.2. Enantioselectivity:  influence of the second coordination sphere for asymmetric 
hydrogenation. 
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Important improvements have been achieved in asymmetric hydrogenation since the initial 
work of Knowles and Horner (Figure 8) 
[115-158]
. In 2001, Noyori and Knowles received the 
Nobel prize for their work in this field 
[159-163]
. Nowadays, this reaction is well developed and 
used at industrial scale for the synthesis of various compounds. 
 
Figure 8. Overview of the development of hydrogenation. 
 
 The first coordination sphere refers to the ligand directly coordinated to the metal. The 
complex, consisting of the metal and the chiral ligand, can form with the substrate two 
diastereomeric intermediates.  
The origin of the enantiomeric excess resides in the difference in energy between the two 
transition states leading from the diastereomeric intermediates to the enantiomeric products 
(Figure 9) 
[164-170]
. The ligand is optimized to discriminate one transition state over the other. 
This can be rationalized with the quadrants illustrated for Rhodium BINAP hydrogenation of 
olefins (Scheme 7) 
[125, 171]
.  
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G≠ =       (
    
    
) 
 
 
Figure 9. Influence of the  G≠ on enantiomeric excess (up) and energetic diagram of 
an asymmetric hydrogenation reaction (down). 
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The position of the phenyl groups on the phosphorous can affect the coordination of the 
substrate to the metal. The phenyl group in the equatorial (position face on) has a higher 
steric hindrance compared to the phenyl in the axial (position edge on). The configuration of 
the ligand dictates the position of the phenyl groups. As illustrated in scheme 7, interactions 
of the carboxylic group of the enamide substrate bound to the catalyst and the phenyl group 
on phosphorus lead to the discrimination of the two diastereotopic intermediates. In the case 
of hydrogenation, the less stable intermediate is the most reactive for addition of hydrogen 
and provides the major enantiomer. 
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Scheme 7. Quadrants illustrated with Rh BINAP and N-acetamido acrylic acid. Grey 
squares represent phenyls in edge-on positions; white squares represent phenyls in face-on 
position. For clarity, BINAP is simplified. 
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The second coordination sphere can have an influence on the discrimination between the 
transition states. In the case of artificial metalloenzymes, the residues around the metal can 
interact with the metal or influence the incoming of the substrate in order to discriminate one 
of the two transition states. In his early report, Whitesides used biotin-avidin technology to 
control the stereoselective addition of dihydrogen to N-acetamidoacrylic acid (Scheme 8). By 
incorporation of an achiral [Rh(diphosphine)(norbordiene)]
+
 complex into avidin, he obtained 
a moderate ee (40% ee S) 
[72]
. 
 
 
Scheme 8. Artificial hydrogenase developed by Whitesides. 
 
 Inspired by this work, many advances have been made in the development of artificial 
hydrogenases using this technology, mainly in the groups of Chan and Reetz 
[172, 173]
. 
 
1.4.3. Influence of the second coordination sphere in asymmetric allylic substitution. 
 
Allylic substitution has become a powerful tool for the creation of C-C bonds 
[174-183]
. The 
allylic substrate is activated by a catalyst and the intermediate attacked by a nucleophile 
leading to the creation of a new bond. The enantiomeric excess is mainly influenced by two 
parameters (Scheme 9). 
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Scheme 9. Representation of the origin of enantioselectivity in asymmetric allylic 
alkylation. 
 
 The isomerisation of the allyl intermediate. Once activated, the allyl intermediate can 
undergo rearrangements via 3 to 1 interconversions.This leads to scrambling of the 
two allyl termini  
 The attack of the nucleophile. The allyl moiety offers two possible sites for attack of 
the nucleophile. The configuration on the asymmetric carbon on the final product is 
determined by the site of attack by the nucleophile. 
  
 Ligands were designed to influence the site of attack of the nucleophile the allyl-metal 
intermediate and to influence the isomerisation rate of the allyl intermediate. An artificial 
metalloenzyme may create an ideal environment in order to direct the attack of the 
nucleophile by introducing steric hinderance. The rate of isomerisation of the allyl 
electrophile can be influenced by generating a confined environment around the metal 
[184-
186]
. 
Some examples in literature reported the use of peptides for asymmetric allylic alkylation 
[187-
192]
.  
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Jäschke reported the creation of an artificial metalloenzyme for allylic amination by 
incorporation of an iridium catalyst to DNA (Scheme 10)
[193]
.  
 
 
Scheme 10. Allylic amination using a iridium catalyst incorporated in DNA developed 
by Jäschke. 
 
 
1.4.4 Molecular recognition: site selective modifications of proteins. 
 
Transition metals are efficient tools for protein modification. Many catalyzed reactions are 
widely used for this purpose 
[194-196]
.  
Based on the studies of Ogo and co workers, Francis reported a method for the reductive 
alkylation of lysines residues at room temperature and neutral pH (Scheme 11) 
[197-199]
. 
Lysozyme has six lysines at its surface and these react in presence of an aldehyde to form 
imines which are reduced by transfer hydrogenation using the water stable 
[Cp*Ir(bipy)(H2O)]SO4.  
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Scheme 11. Reductive alkylation of lysines developed by Francis. 
 
Recently, Valencia, Barluenga and co workers reported the arylation of tyrosine and 
phenylalanine side chains using the Suzuki-Miyaura cross-coupling reaction (Scheme 12) 
[200]
. A peptide sequence containing a tyrosine was previously iodinated and then coupled 
with an aryl trifluoroborate salt under Suzuki-Miyaura conditions.  
 
 
Scheme 12. Arylation of tyrosines and phenylalanine residues using Suzuki-Myaura 
cross-coupling. 
 
In the same spirit, Davis recently reported a Suzuki-Miyaura coupling to a protein at a 
genetically incorporated aryl halide (Scheme 13) 
[201]
. Based on the work of Schultz 
[202]
, he 
introduced unnatural p- halophenylalanine amino acid residues in a maltose binding protein.  
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Scheme 13. Modification of genetically modified protein using Suzuki-Myaura cross-
coupling. 
 
Recently, Davis reported an interesting way to modify proteins using olefin metathesis 
(Scheme 14) 
[203-207]
. A cysteine group on the protein surface is eliminated with O-
mesitylenesulfonylhydroxylamine (MSH) to provide a dehydroalanine residue, which can 
undergo conjugate addition reactions with allylmercaptan to obtain an allylsulfide group on 
the protein surface. He reported that allylsulfide groups are effective substrates for the cross-
metathesis reaction in the presence of the commercially available Hoveyda-Grubbs II catalyst 
under aqueous conditions. 
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Scheme 14. Selective cystein modification using olefin metathesis. 
 
Olefin metathesis offers the advantage to be compatible with the presence of other 
functionalities on the protein. From its discovery, olefin metathesis became one of the most 
useful reactions catalyzed by transition metal complexes. Many research groups contributed 
to develop this reaction and expand its potentiality (Figure 10) 
[208-245]
. Schrock, Grubbs and 
Chauvin were awarded in 2005 with the Nobel Prize for this reaction 
[246-248]
. Ring closing 
metathesis widely contributed to the success of this reaction, finding wide use in total 
synthesis 
[249-252]
. 
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Figure 10. Overview of the development of olefin metathesis. 
 
Since the first mechanistic hypothesis of Chauvin, the mechanism of olefin metathesis is now 
widely accepted 
[253-258]
. After an initialization step, the mechanism occurs by a series of 
[2+2] cycloaddition–retrocycloaddition that release the product and ethylene (Scheme 15). 
 
 
Scheme 15. Mechanism of olefin metathesis. 
 
The potential of metathesis for protein modification is very large. However, in most cases, a 
high catalyst loading is necessary. A biomolecular host protein may result in reducing the 
loading of the catalyst, since the interactions between the two macromolecules may be 
important. 
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Ball described peptide modification using dirhodium metallopeptide catalysts combining 
peptide molecular recognition with the selective modification of aromatic residues (Scheme 
16) 
[259, 260]
. 
 
Scheme 16. Peptide molecular recognition and residue selective modification of 
tryptophane developed by Ball. 
 
In his review, Francis underlined the problem of non specific metal binding to proteins when 
transition metal catalyzed couplings were used for protein modification. This problem can be 
overcome in the case of artificial metalloenzymes since the localization of the metal into the 
protein is ensured by the specific anchoring 
[261]
. 
The presence of the biomolecular scaffold is important for in vivo bioconjugation. Cellular 
media is composed of many elements that can poison the free catalyst and the biomolecular 
scaffold can act as a shield. Recently, Bradley reported that palladium nanoparticles trapped 
within polystyrene microspheres can enter cells and mediate a variety of reactions such as 
allylcarbamate cleavage and Suzuki-Miyaura cross coupling (Scheme 17) 
[262]
. 
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Scheme 17. Cell mediated reactions using trapped palladium nanoparticles developed 
by Bradley. 
 
1.5. Aim of this thesis 
 
 The high stability of (strept)avidin combined with its high affinity towards biotinylated 
compounds offer a large number of promising and challenging applications. In this thesis, we 
focused our efforts on exploiting the potential of streptavidin as a biomolecular scaffold to 
enlarge the scope of artificial metalloenzymes based on the biotin (strept)avidin technology. 
In the first part of this work, it was demonstrated that artificial metalloenzymes can be more 
than a concept. The scope of the system in the case of artificial hydrogenases was determined 
and then the properties of streptavidin were employed to find solutions in order to make this 
system an attractive tool for synthesis. The stability of streptavidin was illustrated in the 
improvement of the allylic alkylation reaction. In parallel, a thermal treatment of cell free 
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extracts was tested to rapidly purify streptavidin isoforms with the aim of implementing 
directed evolution protocols for the optimization of artificial metalloenzymes.  
Until now, streptavidin has been used to generate a chiral environment in asymmetric 
reactions.  A new application of the biomolecular scaffold is presented in the second part of 
this thesis. Based on the principle that the biomolecular scaffold may provide molecular 
recognition, artificial metalloenzymes were designed for site selective modification of 
proteins by investigating suitable reactions to perform the modification. Artificial alkylases 
were tuned for allylic tyrosination of proteins. Finally, an artificial metalloenzyme for olefin 
metathesis was developed. 
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II. Results and discussion. 
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2.1. Artificial hydrogenase based on biotin-streptavidin technology. 
 
2.1.1. Introduction to artificial hydrogenases. 
 
Since 2001, Ward reported on the potential of improvement of artificial hydrogenases by 
chemogenetic optimization (Scheme 18). 
 
 
Scheme 18. Reduction of N-acetamidodehydroaminoacids using artificial 
metalloenzyme based on the biotin-streptavidin technology. 
 
A first generation of artificial hydrogenases was obtained by introduction of an achiral 
rhodium complex in streptavidin mutants in a similar manner to Whiteside’s original 
approach 
[263, 264]
. This first generation contained achiral spacers between the biotin and the 
diphosphine moiety (Figure 11). Chemical optimization was performed by introducing an 
alkyl or an aromatic spacer, which led to significantly altered selectivity and activity of the 
hybrids (Table 3).  
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Figure 11. First generation of artificial hydrogenases using an achiral spacer. 
 
Table 3. Selected results of first generation artificial hydrogenases. 
 
Entry Ligand Protein N-AcPhe 
conv
[a]
 
N-AcPhe 
ee 
[b]
 
N-AcAla 
conv
[a]
 
N-AcAla 
 ee 
[b]
 
1 Biot-1 Sav WT 84 93 quant.
 [c]
 94 
2 Biot-4
meta
-1 S112K 89 -88 quant.
 [c]
 -63 
3 Biot-3
1
-2 S112F 20 -36 quant.
 [c]
 -64 
4 Biot-3
4
-2 S112Q 77 92 quant.
 [c]
 87 
[a]
 conversion in %, 
[b]
 ee in %, positive ee values in favor of the (R)-enatiomer, negatives values in favor of the 
(S)-enatiomer, 
[c]
 quantitative; N-AcPhe: N-acetamidophenylalanine; N-AcAla: N-aceamidoalanine 
 
A new class of artificial metalloenzyme for hydrogenation was generated by introduction of 
an enantiopure amino acid spacer instead of an achiral amino acid (Figure 12) 
[265, 266]
. Dr 
Myriem Skander and Dr Edy Untung Rusbandi selected phenylalanine and proline as chiral 
spacers. Phenylalanine was selected to increase the hydrophobic interactions between the 
aromatic part of the amino acid and the aromatic residues in the pocket of streptavidin. 
Proline was selected with the aim of generating a more rigid structure. Screening of these 
new ligands with the isoforms of streptavidin afforded interesting results. In most cases, the 
chirality of the product was inverted by changing the chirality of the spacer (Figure 13). The 
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second generation catalysts using the proline spacer provided a high stability and tolerance 
toward organic solvents. Catalyses were performed with 45% DMSO as miscible organic 
solvent and ethyl acetate (biphasic system) and only small erosion in conversion and ee were 
observed. 
 
Figure 12. Second generation of artificial hydrogenase using amino acid spacer. 
 
 
Figure 13. Fingerprint display of the result of the chemogenetic optimization of the 
second generation of artificial hydrogenase. 
 
49 
 
2.1.2. “Large scale application” of artificial hydrogenase. 
 
Biocatalysts offer the advantage to be ecologically friendly since little or no toxic chemicals 
are involved in their production. Besides, they are also very selective compared to common 
small catalysts. They can be considered as an alternative for small molecule catalysts for 
application in industry. However, despite these advantages, the cost of production and the 
engineering of these systems can limit their use for large scale applications. The limited range 
of reactions that can be performed with biocatalysts fulfilling the industrial requirements of 
activity, stability and selectivity restricts their application. Artificial metalloenzymes with 
their complementary properties could potentially provide a useful addition to the catalyst 
portfolio. Artificial metalloenzymes strive to combine the structural diversity of 
biomacromolecules with the wealth of transition metal catalyzed reactions. 
 Roelfes discussed in a recent review several criteria that artificial metalloenzyme would have 
to fulfil to be applicable in a large scale reaction, most importantly: a high activity and an 
easy preparation and use of the system 
[267]
. Another point can be addressed: the cost of the 
process. Most often, the catalyst is a high value species. It is therefore desirable to recover the 
catalyst and use it several times. Up to now, only few examples of the application of artificial 
metalloenzymes on a large scale have been reported 
[268]
. 
Several experiments were carried out with artificial hydrogenases to determine if the system 
may be amenable for an application on a larger scale. The investigation of the second 
generation of artificial hydrogenases has demonstrated that artificial metalloenzymes can be 
used in presence of large amounts of organic solvent. This is desirable as the solubility of 
substrates is most often a limiting factor for aqueous catalysis. In the following, the results of 
an investigation into the suitability of artificial hydrogenases based on the biotin-streptavidin 
technology for the larger scale applications are presented. 
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2.1.3. Activity of the artificial metalloenzyme. 
 
First, the activity of the artificial metalloenzyme was tested.  For this purpose, the ratio 
between the substrate and the catalyst was varied from 100 to 1000.  
The amount of the catalyst and the total volume were maintained constant. Accordingly, the 
concentration of the substrate was varied from 6 mM to 60 mM . At concentrations over 60 
mM, the substrate was not fully soluble. 
 
Table 4. Effects of an increase of the ratio between substrate (N-acetamidoacrylic acid) 
and catalyst ([Rh(COD)Biot–1]+  streptavidin WT). 
 
Entry [substrate] 
[a]
 Ratio substrate/catalyst 
[b]
  N-AcAla 
Conv 
[c]
 
  N-AcAla 
ee 
[d]
 
1 6 100 quant. 
[e]
 94  
2 12 200 quant. 
[e]
 94  
3 18 300 quant. 
[e]
 94  
4 30 500 quant. 
[e]
 94  
5 60 1000 85 90  
[a] 
concentration in mM, 
[b]
 equivalent of substrate (N-acetamidoacrylic acid) compared to artificial 
metalloenzyme, 
[c]
 conversion in %, 
[d]
 ee in %, values in favor of the (R)-enatiomer, 
[e]
 quantitative; 5 bars H2, 
16h, room temperature; N-AcAla: N-acetamidoalanine. 
 
The conversion was quantitative down to a catalyst to substrate ratio of 500 and the ee 
remained constant. (94 % ee, entries 1-4, table 4). For a catalyst to substrate ratio of 1000, a 
small erosion in activity and selectivity was observed. (85% conversion 90% ee, entry 5, 
table 4). 
Analytical scale reactions in the laboratory are often carried out on a milligram scale but 
when the scale is increased to the gram scale, differences in conversion and ee are sometimes 
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observed. In the case of artificial metalloenzymes, the amount of  employed material is very 
small since the material is expensive and the yield in the production of the protein is often 
low. Thus, the experiments are performed in general at micromolar scale.  
The artificial metalloenzyme described above containing a proline spacer showed a high 
stability. To investigate if this higher stability observed in small scale reactions would also be 
benifical for the upscaling of the reaction, the amount of the reactants was multiplied by 15 
for this experiment. Streptavidin WT was selected as the protein moiety since this protein 
was available in large amounts and gave good ee’s. 
 
Table 5. Large scale catalysis using [Rh(COD)Biot–(R)-Pro–1]+  streptavidin WT. 
 
Entry Protein amount 
[a]
 Ratio substrate/catalyst 
[b]
  N-AcAla 
Conv 
[c]
 
N-AcAla  
ee 
[d]
 
1 1.67  100 quant. 
[e]
 87  
2 25  100 quant. 
[e]
 87  
3 25  2000 89 40  
[a] 
in mg, 
[b]
 equivalent of substrate (N-acetamidoacrylate) compared to artificial metalloenzyme, 
[c]
 conversion in 
%, 
[d]
 ee in %, values in favor of the (S)-enatiomer, 
[e]
 quantitative; 5 bars H2, 16h, room temperature; N-AcAla: 
N-acetamidoalanine. 
 
Upon increasing the scale by a factor 15 while maintaining the catalyst loading constant, the 
conversion and the ee were unaffected (entry 2, table 5). This result suggests that the artificial 
hydrogenase does not lose its activity or selectivity upon upscaling the reaction. However, the 
substrate/catalyst ratio as increased to 2000, at constant catalyst concentration, a 
heterogeneous mixture was obtained. The conversion remained high but the ee dramatically 
decreased to 40% (entry 3, table 5). 
 
2.1.4. Recycling of the artificial metalloenzyme. 
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Generally, the catalyst is a high value species due to multi step synthesis of the ligand and 
expensive reagents such as precious metals. Very active and operationally stable catalysts 
allow a lower loading but it would still be desirable to recover the catalyst after a catalytic 
run. 
For the purpose of immobilization, Dr Edy Untung Rusbandy developed a strategy relying on 
the high affinity of the biotinylated sepharose for streptavidin (Scheme 19). 
 
 
Scheme 19. Principle of immobilization of the artificial metalloenzyme. 
 
An excess of (strept)avidin is added to the biotin sepharose followed by washing to remove 
the excess protein. The tetrameric protein is fixed on the polymer using one of its four 
binding sites. The remaining (up to three) free binding sites are then employed to bind to the 
biotinylated catalyst. The excess catalyst is then washed off. The immobilized artificial 
hydrogenase is then used in catalysis. This principle of immobilization was exploited to 
recycle the precious artificial hydrogenase. For this experiment, we selected the most 
versatile artificial metalloenzyme based on [Rh(COD)Biot–(R)-Pro–1]+   S112W. 
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Table 6. Recycling of the artificial metalloenzyme [Rh(COD)Biot–(R)-Pro–1]+   
S112W. 
 
Entry Run N-AcAla 
Conv 
[a]
 
N-AcAla  
ee 
[b]
 
1 1st quant. 
[c]
 96  
2 2nd quant. 
[c]
 96  
3 3rd 25 30  
[a]
 conversion in %, 
[b]
 ee in %, values in favor of the (S)-enatiomer, 
[c]
 quantitative; substrate: N-
acetamidoacrylate, 5 bars H2, 16 h, room temperature; N-AcAla: N-acetamidoalanine. 
 
The use of the immobilized artificial metalloenzyme led to similar results compared to the 
system “in solution” (entry 1, table 6). After the first run, the catalyst was recovered by 
filtration and washed. A solution containing the substrate was added to the immobilized 
artificial metalloenzyme for a second run under the same conditions (5 bar H2, 16h, room 
temperature) that led to the same result (entry 2, table 6). A third run, following the same 
procedure, displayed a dramatically reduced activity and selectivity of the catalyst (entry 3, 
table 6). It was concluded that the immobilization on biotin sepharose allows recycling the 
artificial hydrogenase at least once. 
 
2.1.5. Lyophilisation of the artificial metalloenzyme. 
 
With the aim of simplifying manipulation and use of artificial metalloenzymes, their 
lyophilisation was investigated (Scheme 20). 
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Scheme 20. Principle of the lyophilization of the artificial hydrogenase. 
 
A large amount of the artificial metalloenzyme was prepared and then aliquoted into several 
small flasks. Each flask was lyophilyzed and the powder could be easily stocked and handled. 
Once water was added, the artificial metalloenzyme was ready for use. 
An example was carried out with the best artificial hydrogenase, [Rh(COD)Biot–(R)-Pro–1]+ 
 Sav S112W. 
After lyophilisation, the artificial metalloenzyme was dissolved in water in the presence of 
the substrate under 5 bars of hydrogen. The activity and the selectivity of the catalyst 
remained unchanged compared to the non-lyophilized catalyst under the standard screening 
conditions (full conversion, 96% ee in favour of the S enantiomer). 
 
2.2. Artificial alkylase based on the biotin-streptavidin technology. 
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2.2.1. Introduction to artificial alkylases. 
 
 In the Ward group, Dr. Julien Pierron developed an artificial metalloenzyme for the 
formation of new C-C bonds in water using the principle of allylic alkylation 
[269]
. A 
palladium complex was incorporated into streptavidin using a biotinylated diphosphine 
ligand. The protein provided an adequate environment in order to discriminate the attack of 
the nucleophile on the allyl moiety (Scheme 21). The principle of artificial metalloenzyme was 
tested in the allylic alkylation of diphenylacetate (Scheme 22). 
 
 
Scheme 21. Schematic representation of the influence of streptavidin in asymetric allylic 
alkylation. 
 
 As previously demonstrated for the optimization of artificial hydrogenases (see Figure 13). 
The nature of the artificial metalloenzyme allows two kinds of optimization, chemical and 
genetic. Chemical optimization was obtained by modification of the diphosphine or 
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introduction of a spacer between the biotin and the diphosphine moiety. Genetic optimization 
was obtained by point mutation of an amino acid at selected positions. The chemogenetic 
optimization allowed Julien Pierron to obtain good conversions and good enantiomeric 
excesses (Figure 14). Through the screening of different ligands and proteins, he determined 
that the association of the ligand Biot-4
ortho
-1 and the mutant S112A gave the best result 
(90% ee, 90% conversion). Both chemical and genetic strategies can be pursued to improve 
the performance of artificial allylic alkylases. 
 
Scheme 22. Asymetric allylic alkylation of diphenylallylacetate using artificial 
metalloenzyme based on the biotin-streptavidin technology. 
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Figure 14. Fingerprint display of the result of the chemogenetic optimization of the 
artificial metalloenzyme for asymetric allylic alkylation. 
 
A major difficulty encountered in the development of the allylic alkylation of 1,3-
diphenylpropenylacetate was the competing hydrolysis of the substrate under the basic 
conditions required during catalysis. Without any additive, the hydrolysis product is formed 
preferentially over the alkylation product. 
 In order to limit this side reaction, Dr Julien Pieron investigated the effect of detergents such 
as DMB which significantly increased the solubility of the reagents. Better results were 
obtained in term of conversion but the ee dropped from 95% to 90%. Others parameters were 
investigated in order to increase the rate of the alkylation reaction without erosion of 
selectivity. 
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2.2.2. Influence of temperature on the reaction outcome. 
 
The effect of increased temperature on the system in the presence of DMB was tested.  
 
 
Table 7. Effects of the temperature on the activity of the artificial metalloenzyme. 
 
Entry Temperature Conv 
[b]
 ee 
[c]
 
1 0 41 
[a]
 65 
2 5 49 
[a]
 85 
3 25 77 
[a]
 89 
4 40 86 
[a]
 92 
5 60 75 
[a]
 91 
[a]
 only product and hydrolysis product was observed,
 [b]
 conversion in %, 
[c]
 ee in %, values in favor of the (R)-
enantiomer; conversion and ee determined by HPLC; substrate: 1,3-diphenylpropenylacetate, artificial 
metalloenzyme: ([Pd(Ph2allyl)Biot-4
ortho
-1]
+
  S112A), nucleophile: dimethylmalonate, base: K2CO3, 
surfactant: DMB. 
 
The activity and selectivity increased with increasing temperature. At 0°C, the conversion 
and the ee were lowest (entry 1, table 7). The conversion and the ee were highest at 40°C 
(entry 4, table 7) but decreased slightly in comparison at 60°C (entry 5, table 7). The time 
course of the reaction at room temperature was compared to a reaction performed at 40°C 
(Figure 15). The rate of product formation increased at 40°C and the ee remained constant for 
the period monitored for both reactions. 
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Figure 15. Conversion (in red) and ee (in green) profiles of the artificial alkylase at 25°C 
(left) and 40°C (right). 
 
In conclusion, temperature had a positive effect on the reaction. Importantly, an increase of 
the temperature increases the rate of the reaction but also leds to an increase of the ee. 
 
2.2.3. Influence of organic solvent on artificial alkylase. 
 
Within this work, it was demonstrated that certain organic solvents are tolerated by 
streptavidin. The effect of an increased proportion of DMSO as a substitute for the chaotropic 
detergent in catalysis was thus investigated. 
Table 8. Effects of DMSO on the activity and selectivity of the artificial metalloenzyme. 
 
Entry % DMSO Additive Conv 
[b]
 ee 
[c]
 
1 9 -- 20 
[a]
 95 
2 9 DMB 95 
[a]
 90 
3 25 -- 37 
[a]
 96 
4 50 -- 90 
[a]
 95 
[a]
 only product and hydrolysis product was observed,  
[b]
 conversion in %, 
[c]
 ee in %, values in favor of the (R)-
enantiomer; conversion and ee determined by HPLC; substrate: 1,3-diphenylpropenylacetate, artificial 
metalloenzyme: ([Pd(Ph2allyl)Biot-4
ortho
-1]
+
  S112A), nucleophile: dimethylmalonate, base: K2CO3, room 
temperature. 
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It was observed that both the conversion and the ee increased when the proportion of DMSO 
was increased. With 25% DMSO, the conversion was lower than with DMB as an additive 
but the ee was significantly higher (entry 3, table 8). When the amount of DMSO was further 
increased to 50%, the conversion approached the results with DMB and the ee increased 
substantially (entry 4, table 8). Very little erosion of ee occurred. 
SDS page was used to verify the stability of Steptavidin under these modified conditions 
(Figure 16):  the protein is stable with 25% or 50% DMSO and maintains its ability to bind 
biotin. According to SDS page, only a small proportion of the protein is denaturated with 50 
% DMSO. Under these conditions, a band is observed with a mass that corresponds to the the 
monomer but with no binding to Biotin-4-fluorescein. Biotin-4-fluorescein (B4F) was added 
to the sample prior to its loading on the gel. As B4F has a higher affinity for (strept)avidin 
than the biotinylated catalyst, this latter is therefore displaced 
[270, 271]
. The fluorescent nature 
of B4F is used to visualize the functional (biotin-binding) proteins.   
 
Figure 16. Stability of the protein to an increasing amount of organic solvent monitored 
by SDS-PAGE. a) Commasie blue stained gel; b) UV picture of B4F binding activity of protein. 
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2.2.4. Combined effects of temperature and organic solvent. 
 
Since an increase of the proportion of DMSO and an increase in temperature both had a 
positive effect on the catalysis results, we investigated of the simultaneous variation of the 
two parameters. 
 
Table 9. Effects of temperature and DMSO content on the performance of artificial 
allylic alkylases. 
 
Entry Additive Temperature Conv  [b] ee [c] 
1  
25% DMSO 
20 33 
[a]
 96 
2 30 43 [a] 96 
3 40 56 [a] 97 
4  
50% DMSO 
20 87 [a] 94 
5 30 90 [a] 95 
6 40 87 [a] 96 
[a]
 only product and hydrolysis product was observed,  
[b]
 conversion in %, 
[c]
 ee in %, values in favor of the (R)-
enantiomer; conversion and ee determined by HPLC; substrate: 1,3-diphenylpropenylacetate, artificial 
metalloenzyme: ([Pd(Ph2allyl)Biot-4
ortho
-1]
+
  S112A), nucleophile: dimethylmalonate, base: K2CO3. 
 
With 25% DMSO , the enantioselectivity increased from 95% to 97%  and the conversion 
increased from 33 % to 56% (entries 1,2 and 3, table 9). A comparable effect was observed 
with 50% DMSO. The ee was increased from 94% to 96% (entries 4,5 and 6, table 9). 
the high stability of streptavidin towards organic solvents and its thermostability was used to 
improve the output of the reaction.  In the same spirit, these properties of streptavidin can be 
applied at the protein purification process for a high throughput screening of streptavidin and 
its mutants. 
 
2.2.5. High throughput screening exploiting the thermostability of streptavidin. 
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2.2.5.1. Influence of temperature on streptavidin and mutants. 
 
In order to perform a quick screening of protein variants, Dr Alessia Sardo developed a new 
stategy to purify streptavidin 
[272]
. The  purification is the major bottle neck in the production 
of streptavidin and restricts the screening to small library sizes.  Alessia Sardo exploited the 
thermostability of streptavidin  in order to shorten the process and adapt it to a quick 
screening protocol by means of parallel heat treatment of cell free extracts. It was shown that 
streptavidin was stable at high temperature (85°C for several minutes in absence of biotin) 
and this stability can be increased in presence of biotin. First, the effect of the temperature on 
the protein was investigated. We selected streptavidin WT and two other mutants namely 
S112A which gave the highest selectivity in favor of the S enantiomer and S112Q which 
preferentially gave the R enantiomer. These proteins were heated for 5, 10 and 30 min and 
were subsequently analyzed on SDS page (Figure 17). 
 
 
Figure 17. Thermostability of the streptavidin WT and two mutants S112A and S112Q 
monitored by SDS-PAGE. a) and c) Commasie blue stained gel; b) and d) UV picture of B4F binding 
activity of protein. 
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It was noticed that the streptavidin WT was stable at 75°C even after long exposure (30 min). 
The protein was also stable at 85°C.  Besides, the mutant S112Q was stable at 75°C  and 
85°C but the protein denatured more rapidly compared to WT. Furthermore, mutant S112A 
turned out to be the most sensitive of the variants investigated to the exposure of elevated 
temperatures. S112A could tolerate heating for 10 min to 75 °C but denaturation was 
observed for longer heating times or higher temperatures. The observations made by SDS 
page were reflected in catalysis results (table 10). A long exposure to elevated temperatures 
as means for protein purification had a negative effect on the structure of the protein and its 
ability to bind biotin. This was reflected in the catalytic results using heat treated proteins 
(entries 4, 5, 9,10, and 14, table 10). 
 
Table 10. Results of the asymmetric allylic alkylation performed with heated proteins. 
 
Entry Protein Condition Active Site 
[a]
 Conv 
[c]
 ee 
[d]
 
1 
WT 
Standard 3.6 87 
[b]
 65 
2 75 °C, 5 min 3.6 86 
[b]
 65 
3 75 °C, 10 min 3.6 85 
[b]
 64 
4 75 °C, 30 min 3.6 77 
[b]
 30 
5 85 °C, 5 min 3.6 77 
[b]
 34 
6 
S112A 
Standard 4 90 
[b]
 92 
7 75 °C, 5 min 4 87 
[b]
 92 
8 75 °C, 10 min 2 88 
[b]
 93 
9 75 °C, 30 min < 1.6 82 
[b]
 27 
10 85 °C, 5 min < 1.6 80 
[b]
 37 
11 
S112Q 
Standard 4 99 
[b]
 -35 
12 75 °C, 5 min 4 98 
[b]
 -33 
13 75 °C, 10 min 4 99 
[b]
 -35 
14 75 °C, 30 min 2.8 89 
[b]
 -19 
15 85 °C, 5 min 4 99 
[b]
 -35 
[a]
 active sites were determined by B4F titration
 [b]
 only product and hydrolysis product were observed,  
[c]
 
conversion in %, 
[d]
 ee in %, positive ee values in favor of the (R)-enantiomer, negatives values in favor of the 
(S)-enantiomer; conversion and ee determined by HPLC; substrate: 1,3-diphenylpropenylacetate, artificial 
metalloenzyme: ([Pd(Ph2allyl)Biot-4
ortho
-1]
+
  protein), nucleophile: dimethylmalonate, base: K2CO3, 
surfactant: DMB. 
64 
 
 
The best condition for fast extract purification found employed heat treatment at 75°C for 10 
min. 
2.2.5.2. Quick screening of artificial alkylase using thermo-purified cell free 
extracts. 
Cell free extracts are obtained from the expression of the plasmid containing the streptavidin 
gene in E.Coli (Scheme 23). The cell free extracts were heated at 75°C for 10 min and the 
supernatant was recovered. 
 
 
Scheme 23. Cell free extracts production and purification process. 
 
65 
 
 According to SDS-page, a large proportion of components of the cell free extracts other than 
streptavidin can be removed by this method. The supernatant was then used in catalysis. Pure 
protein was added to cell free extracts obtained from cells containing an empty plasmid to 
determine the effects of soluble cell components on catalysis. The results are summarized in 
table 11. 
 
 
 
 
 
Table 11. Results of the asymmetric allylic alkylation performed with heated crude cell 
extracts. 
 
 
Entry Protein  Condition Conv 
[a][b]
 ee 
[c]
 
1 
-- 
 [Pd(3-Ph2allyl)Biot-4
ortho
-1]
+
  39 
[a]
 2 
2 
[Pd(3-Ph2allyl)Biot-4
ortho
-1]
+
  in crude empty 
plasmid extract 
3.1 
[a]
 57 
3 
[Pd(3-Ph2allyl)Biot-4
ortho
-1]
+
  in heated empty 
plasmid extract  
3.0 
[a]
 4 
4 
[Pd(3-Ph2allyl)Biot-4
ortho
-1]
+
  in heated empty 
plasmid extract dialyzed  
25 
[a]
 3 
5 
WT 
[Pd(3-Ph2allyl)Biot-4
ortho
-1]
+
  pure WT 59 
[a]
 79 
6 [Pd(3-Ph2allyl)Biot-4
ortho
-1]
+
  crude extract 0.8 
[a]
 68 
7 [Pd(3-Ph2allyl)Biot-4
ortho
-1]
+
  heated extract  1.0 
[a]
 71 
8 
[Pd(3-Ph2allyl)Biot-4
ortho
-1]
+
  heated extract 
dialyzed 
3.0 
[a]
 79 
9 
[Pd(3-Ph2allyl)Biot-4
ortho
-1]
+
  Spiking with 
pure protein dialyzed  
5 
[a]
 78 
10 
S112A 
[Pd(3-Ph2allyl)Biot-4
ortho
-1]
+
  pure S112A 98 
[a]
 91 
11 
[Pd(3-Ph2allyl)Biot-4
ortho
-1]
+
  Spiking with 
pure protein dialyzed 
9 
[a]
 89 
12 
S112Q 
[Pd(3-Ph2allyl)Biot-4
ortho
-1]
+
  pure S112Q 100 
[a]
 -31 
13 
[Pd(3-Ph2allyl)Biot-4
ortho
-1]
+
  Spiking with 
pure protein dialyzed 
22 
[a]
 34 
[a]
 only product and hydrolysis product was observed,  
[b]
 conversion in %, 
[c]
 ee in %, positive ee values in favor 
of the (R)-enatiomer, negatives values in favor of the (S)-enatiomer; conversion and ee determined by HPLC; 
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substrate: 1,3-diphenylpropenylacetate, artificial metalloenzyme: ([Pd(3-Ph2allyl)Biot-4
ortho
-1]
+
  protein), 
nucleophile: dimethylmalonate, base: K2CO3, surfactant: DMB. 
 
Catalysis in cell free extract without purification led to dramatic erosion in conversion and ee 
compared to the purified protein (entry 6, table 11). The main product observed was 
hydrolysis product. This drop of activity was not caused by a change in concentration of the 
reactants (overall diluton) since catalysis with pure protein under the same condition of 
dilution provided higher activity (entries 1 and 5, table 11). The complex alone (without 
addition of purified streptavidin) used in cell free extracts obtained from the empty plasmid 
culture gave a higher conversion but led surprisingly also to a significant enantiomeric excess 
that must be attributed to components of the cell free extracts (entry 2, table 11). Although 
catalysis with purified extracts led to an enantiomeric excess in the expected range, the 
conversions remained low (entry 7, table 11). These values of ee cannot be attributed to 
impurities since the catalyst alone in heated empty plasmid do not lead to enantiomeric 
excess. (entry 3, table 11). In addition to the above described heat treatment, a dialysis of the 
supernatant of the cell free extracts increased the conversion (entries 4 and 8, table 11). 
Spiking experiments with the mutant S112A gave the expected results (entry 11, table 11) 
meaning an increase in ee, but the spiking experiment with S112Q gave a surprising result 
(entry 13, table 11). 
These experiments demonstrated that cell free extract may be used to evaluate the potentiality 
of different mutants. Supplementary steps were added but significantly reduce throughput, 
which was the initial design idea for the method. Besides, the feasibility of the method is 
severely questioned by the result obtained with S112Q. 
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2.3. Artificial tyrosinase based on the biotin-streptavidin technology. 
 
2.3.1. General. 
 
Francis et al. showed a first example of tyrosine modification, on a protein, employing 
palladium-catalyzed allylic alkylation. 
As a model protein, Chymotrypsinogen A, bearing an accessible tyrosine on the protein 
surface, was selected. The synthesized allylic substrate contained a rhodamine. This 
fluorophore allowed straightforward detection of the protein modification (Scheme 24).  
 
 
Scheme 24. Allylic tyrosination on proteins developed by Francis et al. 
 
The study of Francis et al. is an example of transition metal catalyzed bioconjugation on 
native proteins, but as for other similar methods, peptide sequence-selectivity was not 
achieved. In comparison to the lack of selectivity of many metal-catalysts, nature achieves 
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exquisite selectivity through the use of enzymes. Artificial metalloenzymes might be better 
suited for the desired molecular recognition than traditional small molecule catalyst. 
Based on the experience gathered with artificial metalloenzymes in allylic alkylation, the 
investigation of allylic tyrosination seemed attractive particularly with a view on potential 
sequence selectivity that might be achieved. 
 This work was carried out in collaboration with Ruben Cal during his Master thesis.  
 
 
Scheme 25. Allylic phenolation of cinnamyl acetate using an artificial metalloenzyme 
based on the biotin-streptavidin technology. 
 
In a test reaction, cresol was used as a tyrosine analogue in order to determine the suitable 
conditions for further applications with proteins (Scheme 25).  
 
2.3.2. Optimization of the reaction of allylic phenolation. 
 
Since the cytotoxicity of DMB presents a problem for an application for the modification of 
protein, the allylation reaction was performed in the absence of DMB. Preliminary results 
suggested that the pH has an important influence on the outcome of the reaction (Figure 18). 
No formation of the product was observed for pH ≤ 5 and ≥ 11. The best result was obtained 
with a phosphate buffer at physiological pH (12% conversion, TON= 2).  
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Figure 18. Results of the pH on the palladium catalyzed allylic phenolation. Artificial 
metalloenzyme: [Pd(η3-allyl)(Biot-4ortho-1)]+  streptavidin WT, substrate: cinnamyl acetate, nucleophile: p-
cresol, base: K2CO3, pH 5-6 0.2 M MOPS buffer, 
 
pH 7-8 0.2 M phosphate buffer, 
 
pH 9-11 0.2 M carbonate 
buffer. 
 
 
Sinou et al. as well as other research groups reported a temperature-influence on the 
reactivity of the allylic phenolation 
[273]
. Based on these reports and the knowledge of the 
high thermal stability of streptavidin,
 
the temperature was set to 50°C (Favoring the 
investigation of the system over the purpose to work under physiological conditions).
 
Heating 
the reaction to 50°C improved the conversion to 17%.  
 
2.3.3. Genetic optimization of the artificial metalloenzyme. 
 
Previous studies within the group showed that mutation of the protein has an influence on the 
reactivity, as the second coordination sphere is varied. Mutation at amino acid residue 112, 
was found to have a significant effect on the catalysis outcome. We thus, tested 18 
streptavidin mutants resulting from saturation mutagenesis at position S112 (Figure 19). 
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Figure 19. Result of the screening of 18 S112X streptavidin mutants under optimized 
conditions. Artificial metalloenzyme: [Pd(η3-allyl)(Biot-4ortho-1)]+  protein, substrate: cinnamyl acetate, 
nucleophile: p-cresol, base: K2CO3, 0.2 M phosphate buffer (pH 7.5), 50 °C 
 
 The best results were obtained with basic amino acids at position S112 (25% for S112K and 
32% for S112R). However, the third basic amino acid bearing mutant S112H gave poor 
results (5%). Possibly the positive charge on lysine and arginine at physiological pH had a 
positive influence on the catalyst. The repulsion between the positively charged amino acid 
side chain and the catalyst may relocate the catalyst to a place better accessible for the 
reactants. Alternatively the proximity of the two positive charges may destabilize the 
palladium allyl complex and therefore increased the reactivity of the Pd-allyl intermediate. In 
contrast, histidine has a significantly lower pKa value and could potentially also act as an 
additional ligand with a deleterious effect.  
 
2.3.4. Influence of temperature and pH on the reaction. 
 
Although the reactivity of the allylic phenolation was improved, the conversion remained low 
(compared to the results obtained for the allylic alkylation). To address this problem, the best 
mutant S112R was compared with the protein-free system at various temperatures and pHs 
(Figure 20). 
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Figure 20. Allylic phenolation at various temperatures (right) and at various pHs (left) 
in absence of protein (blue) and in presence of S112R (red). Artificial metalloenzyme: [Pd(η3-
allyl)(Biot-4
ortho
-1)]
+
  protein, substrate: cinnamyl acetate, nucleophile: p-cresol, base: K2CO3. The pH screen 
was performed at 50 °C and the temperature screen at pH 7.5. 
 
The protein-free system is more active than the catalyst incorporated into streptavidin. The 
conversions for the protein-free system increased with temperature and reached total 
conversion at 50°C.  
Further heating (70°C-90°C) led to less product formation. The same profile was reflected 
when the streptavidin incorporated catalyst was tested at various temperatures, albeit with 
much lower conversions.  
The protein-free allylic phenolation was not influenced by the variation of pH, whereas an 
influence of the pH was observed for the catalysis in the presence of streptavidin. A possible 
explanation for this observation is that variation in the pH influences the charge of the protein 
which may cause changes in the conformation of the protein. Since the rate of hydrolysis of 
the starting material can be pH dependent, it can be envisaged that the side reaction can 
compete more efficiently in presence of the protein since the catalyzed reaction is lowered. 
 
2.3.5. Influence of the concentration of the substrate on the reaction. 
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It was supposed that a higher substrate concentration may increase the activity of the catalyst, 
in presence of the protein. Therefore, the mutant screening was repeated using 7.8 mM of the 
allylic substrate. 
 
 
Figure 21. TON of the reactions with 18 streptavidin S112X mutants using 3.9 mM (red) 
and 7.8 mM (blue) of substrate. Artificial metalloenzyme: [Pd(η3-allyl)(Biot-4ortho-1)]+  protein, 
substrate: cinnamyl acetate, nucleophile: p-cresol, base: K2CO3, 0.2 M phosphate buffer (pH 7.5), 50 °C.  
 
The results were compared with the results from previous experiments, where a concentration 
of 3.9 mM of allyl acetate was used (Figure 21). To compare the outcome of these reactions, 
the TON was calculated.  Some mutants (e.g. S112I, S112D) revealed higher turnover 
numbers when 7.8 mM of allyl acetate were used. In contrast, in some cases a decrease of 
activity was observed (e.g. S112A, S112R). These results suggest that no simple relationship 
between concentration and activity exists.  
Until now, we tried to use the artificial metalloenzyme catalysis system developed for allylic 
alkylation for the phenolation of a p-cresol under physiological conditions. However, the 
TON in the reaction was low, despite our efforts to improve the system. A more detailed 
analysis of the reaction may give more clues to improve the system. 
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2.3.6. Detailled analysis of the reaction of allylic phenolation. 
 
During the allylic phenolation, the formation of a white suspension was observed in the 
presence of the host protein (Figure 22). The analysis of the precipitate is described in the 
following paragraphs. 
 
 
 
Figure 22. Catalytic samples after different reaction times 
 
The formation of the white solid is gradual and no suspension appeared in the absence of 
protein. The solid was analyzed using SDS-Page (Figure 23). After centrifugation of a 
reaction sample, the resulting supernatant was removed and the remaining pellet was washed 
with H2O and diethylether prior to analysis.  
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Figure 23. Post catalytic SDS-Page analysis of the white solid and the pure S112R  as 
reference. 
 
The result of the electrophoresis is shown in Figure 23. In the post catalysis sample, two 
protein species are present, the tetrameric streptavidin containing the complex (pure protein), 
as well as a species which did not migrate into the loading gel (this slow migrating protein 
species will be referred to SMPS). Therefore, the SMPS can be either a highly charged or a 
very large species.  
 
2.3.6.1. Investigation on the formation of the SMPS. 
 
Different experiments were performed to determine the nature of the SMPS and to determine 
under which conditions it is formed. Control reactions were performed where individual 
components of the reaction mixture were omitted to identify the cause of the protein 
aggregation. The samples were analyzed by SDS-Page (Figure 24).  
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Figure 24. Post catalytic SDS-Page analysis of the reactions in absence of one reactant. 
a) Commasie blue stained gel; b) UV picture of B4F binding activity of protein.. 1) Marker. In absence of: 2) 
buffer, 3) base, 4) p-cresol, 5) allylic substrate. 6) Sample of the reaction with all reactants. 
 
The SMPS is present in every sample except for the one where the allylic substrate is 
missing. It was concluded that the allylic moieties may interact with the protein. All reactions 
that formed a precipitate also showed the formation of SMPS by SDS-page. 
As it can be seen in Figure 24, SMPS is able to bind biotin. In conjunction with the low 
mobility, this suggests that SMPS is aggregated streptavidin which is, at least in part, 
correctly folded. 
Having identified the link between cinnamyl acetate and the formation of SMPS, possible 
interactions were investigated. To address this problem, the reaction was performed in the 
absence of biotinylated Pd-catalyst. As no formation of the precipitate was observed, it was 
concluded that the catalyst was involved in the formation of the SMPS.  
It can be speculated that the streptavidin can be allylated under the reaction conditions and 
that the allylated protein is the SMPS observed on SDS-Page. This hypothesis is in agreement 
with Bayer’s observation that acetylation of (Strept)avidin strongly affects the migration on 
SDS-Page 
[274]
. Streptavidin monomer contains six tyrosines and four of these tyrosines are 
located at the surface of the protein and are therefore potential nucleophiles. In addition, 
Lysines at the surface of the protein can act as a nucleophile as well.  
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2.3.6.2. Influence of temperature on the formation of the SMPS. 
 
As shown earlier, the conversion is temperature dependent. We thus investigated whether the 
formation of SMPS is also affected by reaction temperature (Figure 25). 
 
 
Figure 25. SDS-Page analysis of S112R Sav after the reaction at different temperatures. 
a) UV picture of BF4 binding activity of protein; b) Commasie blue stained gel  
 
At 40°C reaction temperature, both the complex containing streptavidin tetramer and the 
SMPS are present. At 50°C, almost no streptavidin was observed. At 60°C and 70°C, only 
the SMPS were present. At 80°C and 90°C only traces of the SMPS and no tetrameric 
streptavidin were observed in favor of monomeric Sav (denaturated streptavidin). 
2.3.6.3. Catalytic activity of the SMPS. 
 
To investigate whether the solid protein is active or not, the protein was pre-allylated under 
the reaction conditions in absence of the nucleophile. The formed SMPS was separated by 
centrifugation and employed in the allylic phenolation. 
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The results obtained from the phenolation reaction with the isolated solids are summarized in 
table 12. The SMPS formed using S112R showed a similar activity compared to the reaction 
with untreated pure protein under normal conditions (3.9 mM of cinnamyl acetate) (entries 
1and 2, table 12). In contrast the SMPS formed using S112I and S112E had a higher activity 
compared to the reaction under normal conditions (entries 3, 5, 6 and 8, table 12). For these 
two mutants, the TON obtained with the pre-allylated protein was similar to the TON 
observed with pure protein when a higher amount of cinnamyl acetate (7.8 mM) was used 
(entries 4, 5, 7 and 8, table 12). 
 
Table 12. Allylic phenolation with pre-allylated streptavidin mutants compared to the 
reactions with unmodified protein. 
 
Entry Protein Protein state  Substrate concentration 
[a]
 TON 
1 S112R
 Pure 3.9
 
9 
2 S112R
 Pre-allylated 3.9 9 
3 S112I
 Pure 3.9 4 
4 S112I
 Pure 7.8 11 
5 S112I
 Pre-allylated 3.9 9 
6 S112E
 Pure 3.9 3 
7 S112E
 Pure 7.8 6 
8 S112E
 Pre-allylated 3.9 6 
[a]
 in mM. Artificial metalloenzyme: [Pd(η3-allyl)(Biot-4ortho-1)]+  protein, substrate: cinnamyl acetate, 
nucleophile: p-cresol, base: K2CO3, 0.2 M phosphate buffer (pH 7.5), 50°C.  
 
Based on the results obtained with mutants S112I and S112E (higher activity of the pretreated 
protein compared to untreated), we speculate that the allylation of the protein could 
contribute to the low conversion observed with untreated protein since some of the 
electrophile might get consumed for the allylation of the protein. 
2.3.6.4. LC/MS analysis of the SMPS. 
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Until now no firm proof for the protein modification had been obtained. To determine 
whether the protein is indeed allylated, a tryptic digest of the SMPS (using mutant S112R) 
was performed prior to a LC/MS/MS measurements. This experiment should also allow us to 
idenify possible modifications of the protein. In the LC/MS/MS experiment, the m/z in the 
range of 400-1600 was recorded.  
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         1         12                                        53     59 
Seq S112R        MASMTGGQQMGR/DQAGITGTWYNQLGSTFIVTAGADGALTGTYESAVGNAESR/YVLTGR/ 
Ref S112R        ------------/-----------------------------------------/------/  
SMPS S112R       ------------/-----------------------------------------/------/ 
                                    80   84                 103       112       121 
Seq S112R        YDSAPATDGSGTALGWTVAWK/NNYR/NAHSATTWSGQYVGGAEAR/INTQWLLTR/GTTEANAWK/  
Ref S112R        YDSAPATDGSGTALGWTVAWK/----/NAHSATTWSGQYVGGAEAR/INTQWLLTR/GTTEANAWK/ 
SMPS S112R       ---------------------/----/NAHSATTWSGQYVGGAEAR/INTQWLLTR/---------/  
                         132          144              160 
Seq S112R        STLVGHDTFTK/VKPSAASIDAAK/K/AGVNNGNPLDAVQQ/  
Ref S112R        STLVGHDTFTK/VKPSAASIDAAK/K/AGVNNGNPLDAVQQ/ 
SMPS S112R       STLVGHDTFTK/VKPSAASIDAAK/K/AGVNNGNPLDAVQQ/  
 
Figure 26. Streptavidin S112R peptide fragments detected by LC/MS/MS. Seq S112R represents the complete sequence, Ref S112R corresponds to the 
pure S112R Sav, SMPS corresponds to protein isolated after catalysis. Fragments of the streptavidin S112R peptide sequence are separated with a slash. Possible allylated 
tyrosines are highlighted in yellow and possible allylated lysines are highlighted in green. 
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During tryptic digest, peptide chains are cleaved at the carboxyl side of the amino acids of 
arginines (R) or lysines (K) residues. The results of LC/MS/MS analysis of these fragments are 
illustrated in Figure 26. In addition to the detected fragments of the S112R SMPS (SMPS 
S112R), the complete sequence (Seq S112R) is represented as well as the detected fragments for 
the pure S112R streptavidin (Ref S112R). As it can be seen, not all expected peptide fragments 
from the reference sample were detected. The reason for this is probably that some peptides were 
not ionized and therefore, these peptides were not detected. However, when comparing the 
detected sequences from the reference to corresponding sequences from the SMPS sample, it can 
be seen that two additional peptide sequences (60-80 and 113-121) were not detected in the 
SMPS sample. The absence of these sequences, in the mass spectrum of the post catalysis 
sample, suggests that these peptides were modified during catalysis.  
Only the peptide sequence from amino acid 60-80 bears a tyrosine (Y60) that is accessible in the 
folded protein. The sequence from amino acids 113-121 possesses an accessible lysine, which is 
located near the site where the metal center of the catalyst. Lysines are well known to act as 
nucleophiles in diverse reactions. It can therefore be speculated that next to tyrosines, lysines 
may have been modified. Additionally to the tyrosine at position 60, the peptide sequence from 
amino acids 60-80 bears an accessible lysine at position 80, which could have been allylated as 
well.  
Apart from the two fragments that were detected in the reference but not in the SMPS sample, the 
other sequences which were not detected are potentially allylated sequences, as all of them bear 
an accessible tyrosine (except from sequence 1-12).  
The artificial alkylase based on the biotin-streptavidin technology is a potential candidate for 
proteins modifications. However, various problems would need to be adressed. Acetates as 
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substrate are not ideal due to their low hydrolytic stability. Although it could be demonstrated 
that enantioselectivity can be achieved, the selectivity problems encountered when proteins need 
to be modified sequence-specifically by allylic substitution are potentially far more complex with 
various surface accessible nucleophiles present. A reaction which uses less sensitive substrates 
and makes use of rare residues for modification might offer straightforward approach. Metathesis 
was therefore investigated. 
 
2.4. Artificial ligase based on the biotin-(strept)avidin technology. 
 
2.4.1. General. 
 
Davis and coworkers recently demonstrated the modification of proteins by selectively 
converting the cystein’s thiol group to an allylthioether . The terminal olefin was further modified 
by subsequent metathesis using Hoveyda-Grubbs catalyst (Scheme 26) 
[203-207]
.  
 
 
Scheme 26. Selective modification of protein developed by Davis. 
 
In contrast to a small-molecule catalyst, an embedded catalyst within a protein host 
macromolecule, such as streptavidin, offers the potential for molecular recognition of substrate 
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by interactions between the second coordination sphere amino acids and others functionalities 
present on the substrate. For instance, it is imaginable that a peptide sequence can be recognized 
in the case of a protein target.  
 
 
Scheme 27. Principle of selective modification of proteins using artificial metalloenzyme 
based on biotin-(strept)avidin technology. 
 
For this purpose, artificial metalloenzymes, which can be easily modified through the 
introduction of single point mutations might be successfully employed in order to achieve this 
molecular recognition (Scheme 27).  With the ambitious goal of selective protein modification, the 
creation of an artificial ligase based on the biotin-(strept)avidin technology was investigated. 
 
2.4.2. Synthesis of the biotinylated Hoveyda-Grubbs catalyst (Biot-HG). 
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The synthesis of N-heterocyclic carbenes and their corresponding organometallic complexes is 
extensively reviewed in the literature 
[275-277]
. One of the favored routes for generating NHCs is 
the use of potassium tert-butoxide in conjunction with an imidazolium salt. Potassium tert-
butoxide generates an ether that eliminates tert-butanol upon heating and generates the 
corresponding N-heterocyclic carbene (Scheme 28).  
 
 
Scheme 28. Formation of the N-heterocyclic carbene from the imidazolinium salt in 
presence of 
t
BuOK. 
 
The synthesis of biotinylated NHC could not be achieved by the deprotonation of a biotin 
imidazolinium salt with 
t
BuOK. It appeared that the presence of biotin prevents the reaction 
possibly by consumption of 
t
BuOK caused by the presence of the two acidic urea protons. 
Alternative synthetic pathways were examinated for accessing carbene precursors. Hedrick and 
coworkers described an approach that uses a diamine and pentafluorobenzaldehyde which forms 
the NHC though a Schiff base reaction followed by a nucleophilic attack on the resulting imine to 
form the intermediate (Scheme 29) 
[278]
. 
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Scheme 29. Formation of the NHC using the method developed by Hedrick. 
 
Hedrick investigated on the nature of the aldehyde. The nature of the leaving group in the 
intermediate is important. Depending on its nature, the leaving group can be easily liberated upon 
heating. The pentafluorophenyl leaving group resulted in the formation of pentaflorobenzene 
which has a low boiling that facilitates purification. Grubbs utilized this method to synthesize 
Hoveyda-Grubbs second generation catalyst 
[279]
.  
The method developed by Hedrick was adapted to the synthesis of biotinylated N-heterocyclic 
carbenes. The adduct was synthesized from the biotin diamine and pentafluorobenzaldehyde 
under acidic conditions (Scheme 30). 
 
 
Scheme 30. Synthesis of the biotinylated precursor for the formation of NHC. 
 
The product 45 proved difficult to purify. It was reacted thus further with the Grubbs 1
st
 
generation catalyst. These reactions were conveniently monitored by heteronuclear NMR. As 
outlined in Scheme 31, the formation of the carbene was followed in 
19
F NMR via the peaks 
corresponding to the formation of pentafluorobenzene. The reaction of the carbene generated in 
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situ with Grubbs 1
st
 generation catalyst was monitored by 
31
P NMR. The signal for Grubbs first 
generation (37.5 ppm) was shifted and split into two signals ( 29.4 and 28.5 ppm) (the splitting is 
due to the slow rotation of the NHC that leads to formation of two diastereoisomers) 
accompanied by the appearance of  free tricyclohexylphosphine (11.2 ppm) or 
tricyclohexylphosphine oxide (50.7 ppm).  
 
Scheme 31. Synthesis of Biot-HG monitored by NMR. 
 
Unfortunately, experimental results demonstrated that the synthesis of Biot-HG failed using this 
method. When fluorinated precursor was heated in presence of the complex, peaks corresponding 
to pentafluorobenzene were observed in 
19
F NMR suggesting that the NHC was generated. At the 
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same time, in 
31
P NMR, peaks  were observed at 50.7 ppm and at 11.2 ppm but the peak at 37.5 
ppm as well as the peak at 20.7 ppm on 
1
H NMR disappeared. 
 Another synthetic route was selected whereby the biotin moiety was introduced in the last step 
(Scheme 32). 
 
 
Scheme 32. Synthesis of the biotinylated Hoveyda-Grubbs catalyst (Biot-HG). 
 
The boc-HG 51 was synthetized from the protected imidazolinium salt based on the method 
described by Grela. The biotin moiety was introduced in the last step of the synthesis of Biot-HG 
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where the deprotected boc-HG was coupled to the activated biotin. A significant amount of Biot-
HG was lost during purification on silica gel. Therefore, the complex was purified on Sephadex 
LH 20. This resin was used to purify Biot-HG with dichloromethane as eluant.  
 
2.4.3. Incorporation of the Biot-HG catalyst into the protein. 
 
In order to probe the localization of Biot-HG with Sav, the protein was saturated with 2-(4-
hydroxyazobenzene) benzoic acid (HABA), which has a known binding constant to streptavidin 
[280-282]
. It was subsequently displaced by addition of Biot-HG.  The titration of Sav-HABA with 
Biot-HG was monitored by UV-vis spectroscopy at 506 nm. HABA absorbs at this wavelength 
only when it is incorporated inside the protein. Depending on the affinity of the biotinylated 
complex (e. g. Biot-HG) for the protein, the equivalence point is exected around 4 equivalents 
Biot-HG to streptavidin. 
Aliquots of Biot-HG (0.25 equivalents) were added to HABA  streptavidin (Figure 27). The 
value of absorbance decreased until 4.25 equivalents and the absorption increased slowly 
thereafter as Biot-HG absorbs at this wavelength.  Biot-HG has strong affinity for Sav (much 
stronger than HABA) and up to four equivalents can be accommodated within tetrameric Sav. 
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Figure 27. HABA displacement titration curve by Biot-HG in Sav. 
15M streptavidin WT in 20 mM phosphate buffer (pH 7), 15 eq HABA, aliquots of 5L (0.125 eq) of a 
0.87mM solution of the complex was added. Absorbance was measured at 506 nm. 25°C. 
 
Additional information was gathered by CD spectroscopy (Figure 28). Upon incorporation of 
Biot-HG either within WT Sav or K121G, induced CD signals appeared at 390 and 365 nm 
respectively. Importantly, the CD spectrum Biot-HG ⊂ Sav was unaffected upon lowering the 
pH to 2, thus highlighting the remarkable stability of the system. The shift in induced CD signal 
upon mutation further illustrates the interaction between the host protein and the biotinylated 
guest. 
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Figure 28. Circular dichroïsm of the biot-HG incorporated in the protein. 30L artificial 
metalloenzyme, wavelength: 290-600 nm, step size: 1nm, time per point: 1s, temperature: 40°C. 
2.4.4. Catalytic activity of the artificial lyase. 
 
The activity of the artificial metalloenzyme Biot-HG  Sav was evaluated for prototypical ring 
closing metathesis (RCM) of the diallyltosylamine in aqueous media (Scheme 33). The 
commercial Hoveyda Grubbs 2
nd
 generation catalyst ( HG) was used as reference.  
 
 
Scheme 33. Ring closing metathesis of diallyltosylamine. 
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Table 13. Ring closing metathesis of diallyltosylamine with different catalysts. 
 
Entry Protein Complex Conv 
[a]
 TON 
1 -- HG 97 19 
2 -- Biot-HG 74 15 
3 Streptavidin WT Biot-HG 4 1 
4 Avidin Biot-HG 40 8 
[a]
 conversion in % determined by HPLC reverse phase ; conditions : 0.25 mM protein, 0.73 mM complex, 15.21 mM 
substrate, total volume: 120 L, H2O/DMSO = 5/1, 16h, 40°C. 
 
The commercial HG was active (97% conversion, entry 1, table 13) and Biot-HG was also active 
(74% conversion, entry 2, table 13) but when Biot-HG was incorporated in the streptavidin WT, 
the activity decreased dramatically (4% conversion, entry 3, table 13). The activity increased 
slightly when Biot-HG was incorporated in avidin (40% conversion, entry 4, table 13). 
The activity of the artificial metalloenzyme toward RCM was tested at various pH (Figure 29). 
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Figure 29. Influence of the pH on the activity of artificial metalloenzyme. conditions : 0.25 mM 
protein, 0.73 mM complex, 15.21 mM substrate, total volume: 120 L, H2O/DMSO = 5/1, 16h, 40°C. pH 10-12: 
carbonate buffer, pH 6-8: 0.1M phosphate buffer, pH 4: 0.1M acetate buffer, pH 2: 0.2M KCl/HCl buffer. 
 
For the commercial Hoveyda-Grubbs catalyst, the activity was increased when the pH was 
lowered. The conversion went from 36% at pH 12 to 100% at pH 2. The activity of the Biot-HG 
also was increased when the pH was lowered. The conversion went from 27% at pH 12 to 100% 
at pH 2. The behavior was the same when Biot-HG was incorporated in the (strept)avidin. The 
activity was low in basic conditions (< 5%) and increased from pH 6 to pH 2 to reach 15% 
conversion for streptavidin and 59% for avidin. 
Two hypotheses were developed in order to rationalize the difference in reactivity of avidin 
versus streptavidin. 
 Lysines on the surface of streptavidin coordinate to Biot-HG and thus prevent the olefin 
from binding thereby inhibiting the catalysis. Avidin is a glycosylated protein. The sugars 
may act as a protective shield that made lysines at the surface of the protein less 
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accessible. The lysine at position 121 is near the active site. This amino acid may 
coordinate and deactivate Biot-HG. In these acidic conditions, theses lysines are 
protonated and thus cannot coordinate to the ruthenium complex. 
 Streptavidin and avidin have different isoelectronic points (pI=6 for streptavidin and 
pI=10 for Avidin).  The overall charge of the protein becomes positive when the pH lies 
below their respective pI. Thus, at pH 7, avidin bears an overall positive charge whereas 
streptavidin is negatively charged. 
 
Table 14. Result of the RCM of diallyltosylamine using modified proteins. 
 
Entry Protein Condition Conv 
[a]
 TON 
1 AcStrept WT H2O 1.7 <1 
2 K121G H2O 1.2 <1 
3 rec-Avi H2O 20 4 
4 rec-Avi pH= 4 44 9 
5 rec-Avi pH= 2 49 10 
[a]
 conversion in % determined by HPLC reverse phase ; conditions : 0.25 mM protein, 0.73 mM complex, 15.21 mM 
substrate, total volume: 120 L, H2O/DMSO = 5/1, 16h, 40°C. pH 4: 0.1M acetate buffer, pH 2: 0.2M KCl/HCl 
buffer. 
 
RCM experiments with different proteins were performed to verify these hypotheses. The results 
are collected in table 14. Neither acetylation (AcSav) nor the removal of the close lying K121 
residue (K121G) had a significant impact on the performance of the corresponding hybrid 
catalyst (entries 1 and 2, table 14). This suggests that the lysine residues of Sav have little 
influence on catalysis. 
Rec-Avi, a recombinant form of avidin with a lowered pI=5.5 and limited glycosylation, was 
tested as well (entries 3,4 and 5, table 14) 
[283]
. The activity with the modified protein increased in 
acidic conditions but was comparable to the results obtained with Avidin in the same conditions. 
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We thus conclude that the activity of the artificial metalloenzyme is not critically dependent on 
the pI of the protein. 
2.4.5. Chemical optimization of the artificial ligase. 
 
Based on qualitative docking simulations performed by M. Schmid, a 3-aminobenzoic acid 
spacer was selected (Figure 30). Indeed, the corresponding Biot-mABA-HG was significantly 
more accessible in the docked structures Biot-mABA-HG ⊂ Sav. No significant differences in 
the docked structures for both pseudoenantiomers of either Biot-HG ⊂ Sav or Biot-mABA-HG 
⊂ Sav were apparent. 
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Figure 30. Docking of the complex Biot-HG (up) and Biot-mABA-HG (down) in 
streptavidin. 
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The synthesis of the biotinylated complex Biot-mABA-HG was performed similarly to Biot-HG 
(Scheme 34). 3-aminobenzoic acid was coupled to activated biotin. The benzoic acid function 
was then activated with pentaflorophenol and coupled with the deprotected Hoveyda-Gubbs 
catalyst. 
 
 
Scheme 34. Synthesis of the Biot-mABA-HG. 
 
The activity of the resulting artificial metalloenzymes towards RCM was tested in acidic 
conditions (table 15). 
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As it can be appreciated, the introduction of the aromatic spacer improved the activity of the 
artificial ligase. As it was observed with Biot-HG, the highest activity was obtained with avidin 
at pH 2 (entry 4, table 15). 
 
Table 15. Experiments performed with the Biot-mABA-HG in acidic conditions. 
 
Entry Protein Condition Conv 
[a]
 TON 
1 
Sav 
pH= 4 30 6 
2 pH= 2 42 8 
3 
Avi 
pH= 4 59 12 
4 pH= 2 73 15 
[a]
 conversion in % determined by HPLC reverse phase ; conditions : 0.25 mM protein, 0.73 mM complex, 15.21 mM 
substrate, total volume: 120 L, H2O/DMSO = 5/1, 16h, 40°C. pH 4: 0.1M acetate buffer, pH 2: 0.2 M KCl/HCl 
buffer. 
 
2.4.6. Influence of the presence of metal salt on the reaction. 
 
The activity of the artificial enzyme was greatest at pH 2 with a HCl / KCl 0.2M buffer. 
Hypothesizing that the presence of salt may have a large influence on the activity of the artificial 
metalloenzyme, reactions were performed in presence of various solutions of metal chloride salts 
(Figure 31). 
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Figure 31. Influence of the different metal chloride salts on the activity of Biot-HG ⊂ 
protein for RCM. Conditions : 0.25 mM protein, 0.73 mM complex, 15.21 mM substrate, 0.2 M metal chloride, 
total volume: 120 L, H2O/DMSO = 5/1, 16h, 40°C. 
 
Based on these results, it was observed that metal chloride may influence the activity of the 
artificial metalloenzyme. The highest activity was obtained in presence of CaCl2. 
It can be speculated that metal ions can block lewis basic sites on the protein as would be 
achieved by decreasing the pH. The carboxylic functions on the protein are possible binding 
positions for metals. Streptavidin and avidin have many aspartic acid and glutamic acid in their 
structures (52 residues for streptavidin and 48 for avidin). 
RCM reactions with Biot-HG and Biot-mABA-HG were performed in presence of metal able to 
block anionic sites on the protein (Figure 32). 
As it can be appreciate, the activity was increased in the activity of the artificial metalloenzyme: 
 The activity of Biot-HG ⊂ protein is highest in presence of Ni2+. 
 The activity of Biot-mABA-HG ⊂ protein is highest in presence of Ca2+ and Ni2+. 
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Figure 32. Influence of different metal chloride salts on the activity of Biot-HG ⊂ protein 
(up) and Biot-mABA-HG ⊂ protein (down). Conditions : 0.25 mM protein, 0.73 mM complex, 15.21 
mM substrate, 0.5 M metal chloride, total volume: 120 L, H2O/DMSO = 5/1, 16h, 40°C 
 
A new artificial ligase was created by the incorporation of a biotinylated Hoveyda-Grubbs in 
(strept)avidin. The activity of this artificial metalloenzyme was improved in acidic conditions and 
also in presence of metal chloride salt. It was speculated that the metal was able to block lewis 
basic position on the protein. Mutations of residues bearing carboxylic acid side chain on the host 
protein would be an alternative to improve the activity of the artificial ligase.  
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III. Conclusion   
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Three different artificial metalloenzymes were investigated in this thesis: 
 With practical applications in mind, artificial hydrogenases were screened for their 
performance towards : 
 Increased substrate concentration (up to 60 mM) 
 Decreased catalyst loading (down to 0.1%) 
 Recyclability/immobilization (two catalytic runs with little erosion of the activity and 
selectivity). 
 Storage of “ready to use” lyophilized artificial hydrogenase (no loss of activity). 
Although not truly practical at this point, these results pave the way towards widespread use 
of artificial metalloenzymes. 
 The second part present artificial metalloenzymes for allylic substitution reactions. In this 
context, we have shown that such systems tolerate large portins of organic solvent (up to 50% 
DMSO) and increased temperatures (up to 40°C, with little loss in activity and selectivity). 
To increase throughput, thermal treatment of crude cell extracts was tested as an alternative to 
the lengthy dialysis/chromatography protocol. Despite the stability of Sav, a yet 
uncharacterized cell debris severely limits the usefulness of this approach.  
With chemical biology application in mind and as an extension of the alkylation, phenolation 
(selected as a tyrosine model) was investigated. This study revealed that the host Sav 
undergoes self-allylation. Tryptic digest after a catalytic run suggests allylation at lysine 
residues. 
To circumvent this challenge, a bio-orthogonal reaction was investigated: the olefin 
metathesis. 
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 With the aim of creating artificial metalloenzymes for olefin metathesis, two biotinylated 
Hoveyda-Grubbs catalysts were synthesized. These were for RCM of diallyltosylamine in the 
presence of Sav or Avi. The catalytic performance could be improved either in acidic 
condition or by addition of divalent metal salts. Under optimized conditions, these systems 
rivaled with the “protein-free” Hoveyda-Grubbs catalyst. 
 
Through this work, it was demonstrated that artificial metalloenzymes based on the biotin-
(strept)avidin should not be limited to asymmetric reactions. The potential of such a system 
should be applied for in vivo applications as enzyme. Therefore, two points need to be developed. 
First, it would be worth to combine the outstanding properties of (strept)avidin to compatible 
aqueous reactions able to mimic or provide new functionalities to cellular media. The other 
important point that should be investigated is molecular recognition. This aspect was not 
intensively developed but selected mutations of the host protein should offer a better control of 
interactions between macromolecules. This point would also be a solution for an “efficient 
loading” in protein modification since the lack of selectivity of most of reactions involved 
imposed a high loading of the active species. 
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IV. Experimental part 
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4.1 Reagents and solvents 
 
Substance  Origin  Purity 
(+)-Biotin  Chanzhou Huaren ≥ 99% 
[Pd(Ph2allyl)Cl]2 Own synthesis  
2,3,4,5,6-pentafluorobenzaldehyde Aldrich 98% 
2,3,4,5,6-pentafluorophenol  Aldrich ≥ 99% 
2,4,6-Trimethylaniline Aldrich 98% 
3-aminobenzoic acid Fluka purum, ≥97.0% 
Ac2O Aldrich ACS reagent, ≥98.0% 
Acetonitrile Romil 
SpS ( super purity solvent) UV/gradient 
quality  
Acrylamide   AppliChem 30 % solution 
Allylamine Aldrich ≥99% 
Allylpalladium(II) chloride dimer Aldrich 98% 
Ammonium persulfate Aldrich ≥ 98% 
Anisole  Fluka ≥ 99% 
Avidin  Belovo   
B4F AnaSpec, Switzerland  
Boc2O Aldrich reagent grade, 97% 
Br2 Aldrich reagent grade 
CDMT Aldrich  ≥ 97% 
Coomassie brilliant blue R250 Fluka analytical grade 
CuCl Fluka purum, ≥97.0% 
Cynnamyl acetate Aldrich 99% 
D-biotin-sepharose CL-4B Affiland, Belgium 
suspension in TBS buffer pH 7.4, 
NaN3 0.02 % (w/v)) 
DCC Fluka puriss., ≥99.0% 
Diallylamine Aldrich 99% 
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Didodecyldimethylammonium bromide Fluka purum, ≥98.0% 
Dimethylmalonate Aldrich  
DMAP Aldrich ≥99% 
DMF  Aldrich 
puriss., absolute, over molecular sieve 
(H2O ≤0.005%), ≥99.5% (GC) 
DMSO  Aldrich ACS spectrophotometric grade, ≥99.9% 
DNase I Hoffmann-Roche  
HABA Aldrich ≥98% 
HBr Aldrich 48 wt. % in H2O, ≥99.99% 
Hoveyda-Grubbs  2
nd
 generation Aldrich  
Hoveyda-Grubbs 1
st
 generation Aldrich  
Isobutyl chloroformate aldrich 98% 
N-Acetamidoacrylic acid  Acros  ≥ 99% 
N-Hydroxysuccinimide Fluka purum, ≥97.0% 
N-Methylmorpholine  Fluka  ≥ 98% 
N-N-Diisopropylethylamine  Fluka  ≥ 98% 
Orthoformiate Aldrich anhydrous, 98% 
p-cresol Aldrich puriss. p.a., ≥99.0% 
Phenylethanol Fluka >99% 
Phenylmethylsulfonyl fluoride AppliChem ≥ 99% 
Potassium carbonate Fluka purum p.a., anhydrous, ≥99.0% 
p-toluenesulfonyl chloride Aldrich 
reagent grade, ≥98% 
 
Pyridine Fluka purum, ≥99.0% (GC) 
Rh(COD)2BF4  Umicore   
SDS AppliChem 
20 % solution (molecular biology 
grade) 
Streptavidin Own production  
TEMED Fluka ≥ 99% 
tert-butoxypotassium Aldrich reagent grade, 95% 
tert-butoxypotassium Aldrich 
sublimed grade, 99.99% trace metals 
basis 
105 
 
THF Fluka puriss. p.a., ACS reagent, ≥99.5% (GC) 
trans-1,3-Diphenyl-2-propen-1-ol Aldrich  ≥98.0% (HPLC) 
Tributylamine Aldrich ≥98.5% 
Triethylamine Aldrich puriss. p.a., ≥99.5% (GC) 
Trimethylsulfonium hydroxide  Fluka  0.25M in MeOH 
Triphenylphosphine Fluka puriss., ≥98.5% 
Water Romil SpS ( super purity solvent) 
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4.2 Synthesis. 
 
General: 
1
H, 
13
C and 
19
F spectras were obtained on a Bruker 400 MHz, 500 MHz, 600 MHz. 
Chemical shifts are reported in ppm (parts per million). Signals are quoted as s (singulet), d 
(doublet), t (triplet), br (broad), and m (multiplet). Electron Spray Ionization Mass Spectra (ESI-
MS) were recorded on a Bruker FTMS 4.7T bioAPEX II. 
 
The following compounds were prepared as described in the literature 
[111, 263, 265]
 
 
 
 
 
 
Synthesis of 1,3 diphenylpropenacetate 37 
[284]
. 
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To a solution of trans-1,3-Diphenyl-2-propen-1-ol (2 g, 9.51 mmol) in Ch2Cl2 was added 
anhydride acetic (4.5 ml, 47.56 mmol) and Et3N (6.6 ml, 47.56 mmol). The reaction mixture was 
stirred for 16 h. The solvent was removed by vaccum and purified on silica gel using 
hexane/AcOEt 10:1 as eluent to yield the product 37 as colorless oil. (2,13 g, 88%) 
1
H NMR (400 MHz, CDCl3) δ: 7.49 – 7.23 (m, 11H), 6.67 (d, J = 15.8 Hz, 1H), 6.48 (d, J = 6.8 
Hz, 1H), 6.38 (dd, J = 15.8, 6.8 Hz, 1H), 2.16 (s, 3H). 
13
C NMR (101 MHz, CDCl3) δ: 170.46, 
139.68, 136.60, 133.03, 129.07, 129.02, 128.62, 128.51, 127.94, 127.49, 127.14, 21.79. 
 
 
Synthesis of allyl ether 42. 
Allylpalladium chloride dimer (13.5 mg, 0.07 mmol) and triphenylphosphine (18 mg, 0.28 mmol) 
were dissolved in 3 ml dry and degassed THF. p-Cresol (183 mg, 1.7 mmol) cynnamyl acetate 
(250 mg, 1.42 mmol) and pyridine (240 µl, 2.84 mmol) were added. The reaction mixture was 
stirred at 50 °C for 16h. The solution was extracted three times with NaHCO3. The combined 
aqueous layers were re-extracted three times with CH2Cl2. The combined organic layers were 
dried over MgSO4, filtered and evaporated to dryness. The product was purified on silica gel 
using hexane/ethyl acetate 20/1 as eluant to yield 42 as a white solid. (140 mg, 44%) 
1
H-NMR: (500 MHz, CDCl3) δ: 7.42 (d, 2H, 7.6 Hz), 7.33 (t, 2H, J = 7.6 Hz), 7.26 (d, 1H, J = 
7.6 Hz), 7.10 (d, 2H, J = 8.3 Hz), 6.87 (d, 2H, J = 8.3 Hz), 6.73 (d, 1H, J = 16.0 Hz), 6.44 (dt,
 
J = 
5.7, 16.0 Hz, 1H), 4.68 (d, 2H, J = 5.7), 2.29 (s, 3H).
13
C-NMR (50 MHz, CDCl3) δ: 136.93, 
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133.24, 130.55, 130.34, 128.98, 128.25, 126.98, 125.14, 115.07, 63.16 20.89. MS for C16H16O: 
222.6 [M+H]
+
 
 
 
Synthesis of 2,3-dibromopropan-1-amonium bromide 47 
[285]
. 
Allylamine (13.16 ml, 175 mmol) was dissolved in 100ml of water and cooled in a ice bath. HBr 
(19.6 ml, 193 mmol) was added dropwise at 0°C under stirring. A solution of bromine in water 
(13.5 ml, 263 mmol) was then added. The reaction was stirred at room temperature for 4 hours. 
The solvent was then removed by vaccum and the solid was recrystallized in MeOH to yield the 
product 47 as a white solid. (37.4g, 72%) 
1H NMR (400 MHz, D2O) δ: 4.51 (dddd, J = 9.5, 8.9, 4.5, 3.2 Hz, 1H), 3.96 (dd, J = 11.0, 4.6 
Hz, 1H), 3.75 (ddd, J = 17.2, 12.6, 6.0 Hz, 2H), 3.37 (dd, J = 14.1, 9.6 Hz, 1H). 
13
C NMR (101 
MHz, D2O) δ: 46.98, 44.74, 33.74. 
 
 
Synthesis of  N
1
,N
2
-dimesitylpropane-1,2,3-triamine 48 
[286]
. 
Amine 47 (10g, 33.6 mmol) was dissolved in mesitylamine (61ml, 433.3 mmol). The mixture 
was heated under nitrogen at 120°C for 19 hours. The excess of mesitylamine was removed by 
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distillation. The oil was dissolved in a mixture of Et2O/ NaOH 15% (1:1) and was stirred for 
several minutes. The organic phase was washed with brine and dried over Na2SO4. The solvent 
was evaporated and the crude was purified on silica gel using CH2Cl2/MeOH/NEt3 4:1:0.1 as 
eluent to yield 48 as brown oil. (3.64 g, 33%) 
1
H NMR (400 MHz, CDCl3) δ: 6.84 (dd, J = 7.3, 4.0 Hz, 4H), 3.53 – 3.39 (m, 2H), 3.19 (dd, J = 
11.8, 5.7 Hz, 1H), 2.92 (dd, J = 5.0, 2.7 Hz, 2H), 2.37 – 2.17 (m, 18H).13C NMR (101 MHz, 
CDCl3) δ: 144.03, 142.33, 131.78, 131.14, 130.23, 130.20, 129.89, 129.28, 59.13, 51.91,  45.36, 
20.98, 20.93, 19.59, 18.75. ESI-MS for C21H31N3: [M+H]
+ 
 
 
 
Synthesis of  biotinylated diamine 44. 
Biotin NHS (230.7 mg, 0.67 mmol) and 48 (200 mg, 0.61 mmol) was dissolved in DMF. Et3N 
(0.25 ml, 1.83 mmol) was added and the reaction mixture was stirred 16 hours at room 
temperature. The solvent was removed and the crude product was purified on silica gel using 
CH2Cl2/MeOH 8:1 as eluant to yield 44 as a pale solid. (211 mg, 62%) 
1
H NMR (400 MHz, CDCl3) δ 6.77 (dd, J = 15.3, 5.2 Hz, 4H), 5.99 (s, 1H), 5.79 (s, 1H), 4.42 – 
4.27 (m, 1H), 4.28 – 4.17 (m, 1H), 3.62 (m, 1H), 3.55 – 3.37 (m, 2H), 3.09 – 2.91 (m, 2H), 2.83 – 
2.66 (m, 2H), 2.41 (dd, J = 42.4, 12.8 Hz, 1H), 2.23 – 2.09 (m, 18H), 1.66 (m, 4H), 1.39 (m, 2H). 
ESI-MS for C31H45N5O2S: 552.3 [M+H]
+ 
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Synthesis of biotinylated imidazolinium chloride salt 57. 
To the diamine 44 (100 mg, 0,18 mmol) and NH4Cl (9.69 mg, 0.18 mmol) triethyl orthoformate 
was added (1 ml, 5.44 mmol). The mixture was stirred overnight at 120°C. The mixture was 
dissolved in a small amount of CH2Cl2 and poured in Et2O. The solid was washed with Et2O and 
purified on a small plug of silica gel using CH2Cl2/MeOH 10:1 to yield 57 as a white solid. (45 
mg, 41%) 
1
H NMR (400 MHz, CDCl3) δ: 8.61 (d, J = 11.9 Hz, 1H), 7.03 – 6.77 (m, 4H), 6.64 (m, 1H), 6.12 
(m, 1H), 5.37 – 5.11 (m, 1H), 4.65 – 4.33 (m, 2H), 4.24 (s, 1H), 3.99 (m, 1H), 3.87 – 3.60 (m, 
1H), 3.37 – 3.15 (m, 1H), 2.70 (m, 1H), 2.64 – 2.46 (m, 1H), 2.22 (m, 20H), 1.66 – 1.34 (m, 4H), 
1.35 – 1.12 (m, 2H). ESI-MS for C32H44ClN5O2S: 562.32 [M-Cl]
+ 
 
 
 
Synthesis of biotinylated intermediate 45. 
Diamine 44 (100 mg, 0.18 mmol), pentafluorobenzaldehyde (22 µl, 0.18 mmol) and anhydrous 
sodium sulfate were dissolved in 5 ml CH2Cl2/acetic acid (1:1). The mixture was stirred 
overnight at room temperature. The solvent was evaporated and the solid was washed with Et2O. 
45 was directly used for the following reaction without further purification. 
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19
F NMR (376 MHz, CDCl3) δ: -137.47 (t, J = 19.2 Hz), -146.13 – -146.45 (m), -153.57 – -
154.29 (m), -162.18 (td, J = 21.7, 10.7 Hz), -162.26 – -162.86 (m). 
 
 
Synthesis of tert-butyl (2,3-bis(mesitylamino)propyl)carbamate 49 
[286]
. 
Amine 48 (1.8g, 5.53 mmol) and Boc2O (1.2g, 5.53 mmol) were dissolved in dry and degassed 
CH2Cl2 and cooled to 0°C. DMAP (67mg, 0.56 mmol) was added to the reaction and stirred at 
0°C for 30 min and then at room temperature for 4 hours. The reaction mixture was washed twice 
with water and brine and the organic phase was dried over Na2SO4. The solvent was evaporated 
and the product was purified on silica gel using Hexane/AcOEt 7:1 as eluent to yield 49 as a 
white solid.(1.67g, 71%) 
1
H NMR (400 MHz, CDCl3) δ: 6.80 (d, J = 7.1 Hz, 4H), 3.44 (m, 2H), 3.26 (m, 2H), 3.16 – 3.05 
(m, 1H), 2.87 (dd, J = 12.3 Hz, 4.4Hz, 1H), 2.22 (m, 18H), 1.45 (s, 9H). 
13
C NMR (101 MHz, 
CDCl3) δ: 156.87, 143.93, 141.73, 131.81, 131.44, 130.40, 130.21, 129.86, 129.28, 79.84, 57.48, 
51.22, 43.68, 28.79, 20.92, 20.89, 19.40, 18.72. ESI-MS for C26H39N3O2: 426.31 [M+H]
+
 
 
 
Synthesis of boc-imidazolinium chloride salt 50 
[286]
. 
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Diamine 49 (2g, 4.7 mmol) and NH4Cl (265mg, 4.7 mmol) were dissolved in 10 ml of neat 
triethyl orthoformate. The mixture was heated at 120°C under an inert atmosphere for 16 hours. 
The reaction mixture was allowed to cool down to room temperature and Et2O was added. The 
precipitate was filtered and washed with a large amount of Et2O to yield the product 50 as a white 
solid. (1.98g, 89%) 
1
H NMR (400 MHz, CDCl3) δ: 8.56 (s, 1H), 6.94 (s, 4H), 4.78 (dd, J = 12.3, 8.4 Hz, 1H), 4.46 (t, 
J = 12.1 Hz, 1H), 3.70 (dd, J = 18.5, 11.2 Hz, 1H), 3.34 (dt, J = 13.0, 4.6 Hz, 1H), 2.33 (dd, J = 
43.0, 14.4 Hz, 17H), 1.35 (s, 9H). ESI-MS for C27H38ClN3O2: 436.29 [M-Cl]
+
 
 
 
Synthesis of boc-Hoveyda-Grubbs catalyst 51 
[287, 288]
.  
A suspension of 
t
BuOK (112 mg, 0.99 mmol) was added to the imidazolinium salt 50 (471 mg, 
0.99 mmol) in dry and degassed THF (15 ml). The mixture was stirred 30 min at room 
temperature. The yellow solution was transferred into a flask containing Hoveyda-Grubbs 1
st
 
generation (500 mg, 0.83 mmol) in benzene (75 ml) and stirred at 80°C. After 1 hour, CuCl (99 
mg, 0.99 mmol) was slowly added to the solution and stirred for an additional hour at 80°C. The 
solvent was evaporated and the product 51 was purified on silica gel using cyclohexane/AcOEt 
10:1 as eluent. (277 mg, 44%). 
1
H NMR (500 MHz, CD2Cl2) δ: 16.32 (s, 1H), 7.48 – 7.43 (m, 1H), 7.05 – 6.95 (m, 4H), 6.88 – 
6.74 (m, 3H), 4.82 (m, 1H), 4.43 (m, 1H), 4.18 (t, J = 10.8 Hz, 1H), 3.86 (t, J = 8.9 Hz, 1H), 3.30 
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(m, 2H), 2.33 (m, 18H), 1.30 (s, 9H), 1.17 (d, J = 5.1 Hz, 6H).
 13
C-NMR (125 MHz, CD2Cl2) δ: 
151.25, 144.28, 138.28, 128.98, 128.96, 121.48, 121.37, 112.96, 78.68, 74.38, 63.89, 55.36, 
42.04, 27.23, 20.19, 20.06, 19.99. ESI-MS for C37H49Cl2N3O3Ru: 720.25 [M-Cl]
+ 
 
 
 
Synthesis of biotinylated Hoveyda-Grubbs catalyst Biot-HG 
Complex 51 (40 mg, 0.053 mmol) was dissolved in CH2Cl2 (2 ml) and HCl gas was bubbled 
through the solution for 1 hour at room temperature. The gaseous HCl was generated by the drop-
wise addition of concentrated H2SO4 to NH4Cl. The solution was stirred for 2 hours at room 
temperature. The deprotection step was monitored by thin-layer chromatography (TLC) 
(Hexane/AcOEt  2:1). The solvent was evaporated and the resulting green solid was dissolved in 
DMF (2 ml). Biotin pentafluorophenol (22 mg, 0.053 mmol) and Et3N (0.2 ml, 1.4 mmol) was 
added to the solution and stirred for 16 h at room temperature. The solvent was removed at 
reduced pressure. The crude product was purified on sephadex LH 20 eluted with CH2Cl2 to yield 
Biot-HG as a green solid. (27 mg, 58%). 
1
H-NMR (500 MHz, CD2Cl2) δ: 16.36 (s, 1H), 7.49 (m, 1H), 7.03 – 6.97 (m, 4H), 6.90 – 6.77 (m, 
3H), 4.85 (m, 1H),  4.52 (m, 1H), 4.43 (m, 1H), 4.36 (m, 1H), 4.18 (m, 1H), 3.82 (m, 1H), 3.57 
(m, 1H), 3.33 (m, 1H), 3.06 (m, 1H), 2.89 (m, 1H), 2.59 (m, 1H), 2.42 – 1.97 (m, 20H), 1.68 – 
1.54 (m, 4H), 1.42 – 1.32 (m, 2H), 1.21 (m, 6H). 13C-NMR (125 MHz, CD2Cl2) δ: 174.7, 152.2, 
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145.0, 143.1 138.7, 136.7, 129.9, 129.8, 122.3, 112.9, 75.2, 63.5, 61.6, 59.9, 55.3, 45.7, 40.5, 
35.5, 29.6, 27.9, 26.6, 25.2, 21.2, 20.5, 17.95. ESI-MS for C42H55Cl2N5O3RuS:  846.28 [M-Cl]
+
. 
 
 
Synthesis of biotinylated benzoic acid 55 
[263]
. 
Isobutyl chloroformate (0.32 ml, 2.47 mmol) was added to a solution of biotin (500 mg, 2.05 
mmol) in DMF (40 ml) containing tri-N-butylamine (0.64 ml, 2.69 mmol). After 10 min at room 
temperature, the mixture was slowly added to a suspension 3-aminobenzoic acid (4.1 mmol)) in 
40 ml DMF at 5°C and was stirred at 5 °C for 2 hrs, the solvent was removed and the crude 
precipitate was dissolved in warm aqueous ethanol (1:1, 36 ml total). The mixture was acidified 
with 2.0 N HCl to pH 2 and kept at 0 °C for 12 hours. The resulting precipitate was filtered, 
washed with water and dried under vacuum to yield 55 as a white solid. (467mg, 63%) 
1
H NMR (400 MHz, DMSO) δ: 12.91 (s, 1H), 10.04 (s, 1H), 8.21 (t, J = 1.7 Hz, 1H), 7.80 (dd, J 
= 8.1, 1.1 Hz, 1H), 7.58 (d, J = 7.8 Hz, 1H), 7.39 (t, J = 7.9 Hz, 1H), 6.43 (s, 1H), 6.35 (s, 1H), 
4.29 (dd, J = 7.6, 5.2 Hz, 1H), 4.16 – 4.08 (m, 1H), 3.15 – 3.06 (m, 1H), 2.80 (dd, J = 12.4, 5.1 
Hz, 1H), 2.56 (d, J = 12.4 Hz, 1H), 2.30 (t, J = 7.4 Hz, 2H), 1.69 – 1.27 (m, 6H). 13C NMR (101 
MHz, DMSO) δ: 172.29, 168.06, 163.58, 140.38, 132.07, 129.79, 124.63, 123.97, 120.63, 61.90, 
60.06, 56.25, 40.72, 37.08, 29.08, 28.96, 25.91. ESI-MS for C17H21N3O4S: 362.12 [M-H]
- 
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Synthesis of activated biotinylated benzoic acid ester 56. 
The benzoic acid derivative 55 (200mg, 1.37 mmol) and N,N'-dicyclohexylcarbodiimide 
(283 mg, 1.37 mmol) were dissolved in DMF (35 ml). A solution of pentafluorophenol (506 mg, 
2.75 mmol) in 10 ml DMF was added and the reaction solution was stirred for 16 hours at room 
temperature. The reaction mixture was filtered and the solvent was evaporated. The resulting 
solid was washed with hexane to yield the activated ester 56 as a white solid. (257 mg, 88%). 
1
H NMR (400 MHz, DMSO) δ: 10.25 (s, 1H), 8.52 (s, 1H), 7.93 (dt, J = 18.0, 9.0 Hz, 1H), 7.82 
(d, J = 8.0 Hz, 1H), 7.57 (t, J = 8.0 Hz, 1H), 6.44 (s, 1H), 6.35 (s, 1H), 4.38 – 4.23 (m, 1H), 4.12 
(dd, J = 8.9, 3.0 Hz, 1H), 3.18 – 3.04 (m, 1H), 2.90 – 2.68 (m, 1H), 2.56 (d, J = 12.4 Hz, 1H), 
2.40 – 2.23 (m, 2H), 1.83 – 1.51 (m, 6H). 13C NMR (101 MHz, DMSO) δ: 172.63, 164.84, 
163.58, 142.05, 141.07, 134.54, 130.85, 128.46, 127.14, 126.30, 122.96, 121.08, 61.90, 60.06, 
56.25, 40.72, 37.09, 34.21, 30.25, 28.96, 25.82. 
19
F NMR (376 MHz, DMSO) δ: -153.22, -
157.27, -162.00. ESI-MS for C23H20F5N3O4S: 552.10 [M+Na]
+ 
 
 
 
Synthesis of biotinylated complex Biot-mABA-HG 
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Complex Biot-mABA-HG was synthesized following the procedure for the synthesis of the 
related complex Biot-HG using the boc-protected complex 51 (35 mg, 0.066 mmol) and the 
activated ester 56 (50 mg, 0.066 mmol). (23 mg, 35%). 
1
H-NMR (500 MHz, CD2Cl2) δ: 16.38 (s, 1H), δ 7.89 (s, 1H), 7.71 (s, 1H), 7.49 (m, 1H), 7.38 
(m, 1H), 7.25 (m, 1H) 7.06 – 6.94 (m, 4H), 6.90 - 6.77 (m, 3H), 4.84 (m, 1H), 4.73 (m, 1H)  4.60 
(m, 1H), 4.34 (m, 1H), 4.19 (m, 1H), 3.93 (m, 1H), 3.75 (m, 1H), 3.57 (m, 1H), 3.04 (m, 1H), 
2.80 (m, 1H), 2.55 (m, 1H), 2.38 - 2.01 (m, 20H), 1.70 – 1,52 (m, 4H), 1.41 – 1.33 (m, 2H), 1.19 
(m, 6H).
 13
C-NMR (125 MHz, CD2Cl2) δ: 152.3, 151.8, 145.1, 142.8, 138.5, 134.4, 131.1, 130.3, 
129.9, 129.5, 122.8, 122.3, 118.2, 113.0, 75.2, 63.6, 61.5, 60.6, 55.6, 42.1, 40.5, 36.5,  29.6, 27.9, 
27.6, 25.1, 21.0, 20.7, 17.8. ESI-MS for C49H60Cl2N6O4RuS: 965.33 [M-Cl]
+
. 
 
 
Synthesis of N-tosyldiallylamine 52 
[289]
. 
Diallylamine (6.33 ml, 51.4 mmol) and toluene-4-sulfonyl chloride (14.7 g, 77.2 mmol) were 
dissolved in CH2Cl2 (100 ml) and cooled to 0°C. Et3N (20 ml, 154.3 mmol) was added over the 
course of 10 min and the reaction solution was stirred for 16 hours at room temperature. The 
reaction solution was placed in a separatory funnel and the organic phase was washed with water 
and brine, the organic phase was collected and dried over Na2SO4. The solvent was evaporated 
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and the resulting oil was purified on silica gel using CH2Cl2 to yield 52 as colourless oil. (11.8 g, 
91%). 
1
H NMR (400 MHz, CDCl3) δ: 7.73 – 7.67 (m, 2H), 7.30 (d, J = 8.0 Hz, 2H), 5. 61 (ddt, J = 17.3, 
9.8, 6.3 Hz, 2H), 5.15(m, 2H), 5.12 (m, 2H), 3.80 (d, J = 6.3 Hz, 4H), 2.42 (s, 3H). 
13
C NMR 
(101 MHz, CDCl3) δ: 143.64, 137.78, 133.04, 130.08, 127.54, 119.34, 49.74, 21.89. ESI-MS for 
C13H17NO2S: 252.1 [M+H]
+
. 
 
 
Synthesis of metathesis product 53 
Diolefin 52 (100 mg, 0.39 mmol) and Hoveyda-Grubbs  2
nd
 generation catalyst (12 mg, 0.02 
mmol) were dissolved in 5ml CH2Cl2 and stirred at room temperature for 1 hour. The reaction 
mixture was filtered on a plug of silica gel using dichloromethane as eluant to yield 53 as a white 
solid. (79 mg, 88%). 
1
H NMR (400 MHz, CDCl3) δ: 7.72 (d, J = 8.2 Hz, 2H), 7.31 (d, J = 8.0 Hz, 2H), 5.70 – 5.58 (s, 
2H), 4.11 (s, 4H), 2.42 (s, 3H). 
13
C NMR (101 MHz, CDCl3) δ: 143.82, 134.67, 130.15, 127.81, 
125.84, 55.24, 21.93. ESI-MS for C11H13NO2S: 224.12 [M+H]
+ 
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4.3 Catalysis procedures. 
 
General Aspects. High purity solvents were used to perform catalysis. All aqueous and organic 
solvents were flushed with nitrogen during at least three hours. All manipulations were 
performed in a nitrogen atmosphere glove box. RCM reactions were performed at air. 
 
Hydrogenation at different concentration of substrate. 
 
 [Rh(COD)2]BF4 was dissolved in DMSO (4 mg, 16 ml DMSO), 1.56 µmol of this solution was 
added to the appropriate aliquoted ligand (2.02 µmol, 1.3 equiv. with respect to the metal source). 
This solution was stirred for ca. 10 min. 
 A Pyrex tube (volume ca. 3 ml) was placed in an autoclave and charged with an N-
acetamidoacrylic acid solution in MES buffer 0.38M. The volume was adjusted with water to 900 
µl. The protein solution in water was then added (100 µl of a 0.207 mM solution, 0.0207 µmol of 
the tetramer). The precatalyst solution in DMSO (100 µl, 0.062 µmol) was added last. The 
resulting mixture was vortexed, removed from the glove box and hydrogenated at 5 bars H2 for 
15h.  
Permabond-L-Chirasyl-Val (Macheray-Nagel), 25 m x 0.25 mm column: He carrier 
gas: 1.2 bar, inlet injector 280°C, oven (85°C; 10 min, 8°C/min; 135°C; 0 min, 
10°C/min; 180°C; 35min), FID detector 200 °C; retention time: 
Methyl N-acetylacetamidoacrylate: 9.3 min 
Methyl (R)-N-acetylacetamidoalanine: 17.2 min 
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Methyl (S)-N-acetylacetamidoalanine: 18.5 min 
 
Hydrogenation procedure for recycling of Immobilized Artificial Metalloenzymes.  
 
The commercial suspension of D-biotin-sepharose CL-4B (105 µL, which corresponds to 0.031 
µmol biotin, capable of immobilizing 0.031 µmol tetrameric (strept)Avidin) (Affiland, Belgium, 
suspension in TBS buffer pH 7.4, NaN3 0.02 % (w/v)) was decanted and washed with water to 
afford wet beads, which were resuspended in water (105 µL total volume). The protein solution 
(0.062 µmol, 2 equiv. vs. biotin sepharose, 300 µL) was added. After ca. 10 min incubation, the 
immobilized protein (containing 0.031 µmol of protein, corresponding to 0.093 µmol, free active 
sites) was washed at least three times with H2O to remove the unbound protein and flushed with 
nitrogen for three hours. The precatalyst solution in DMSO (100 µl, 0.062 µmol, 0.66 equiv. with 
respect to the free biotin-binding sites) was added last and was incubated with the immobilized 
protein for 10 min. The immobilized catalyst was subjected to several cycles of washing and 
decanting. The catalytic runs were performed according to the standard orbital shaking 
procedure. After the catalytic run, the immobilized catalyst was decanted, washed and the 
solution were analyzed. An N-acetamidoacrylic acid solution in MES buffer 0.38M (260 µl of a 
23.85 mM solution, 6.20 µmol) was added to the immobilized catalyst and subjected to another 
catalytic run. 
Permabond-L-Chirasyl-Val (Macheray-Nagel), 25 m x 0.25 mm column: He carrier 
gas: 1.2 bar, inlet injector 280°C, oven (85°C; 10 min, 8°C/min; 135°C; 0 min, 
10°C/min; 180°C; 35min), FID detector 200 °C; retention time: 
Methyl N-acetylacetamidoacrylate: 9.3 min, 
Methyl (R)-N-acetylacetamidoalanine: 17.2 min, 
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Methyl (S)-N-acetylacetamidoalanine: 18.5 min, 
 
General procedure for allylic alkylation. 
 
The biotinylated ligand (8 mM stock-solution) and the Pd-precursor (6.8 mM stock solution) 
were dissolved in DMSO and mixed and stirred for 5 min at room temperature. Streptavidin was 
dissolved in water (275 µL of a 82 μM stock solution, 0.092 µmol, 1.4 eq. active sites vs. metal) 
and mixed in a vial with the Pd-complex (20 µL of the stock-solution, 0.068 µmol metal) and 
stirred at room temperature for 30 min. Dimethylmalonate (43 µL, 0.34 mmol) and 1,3-
diphenylpropenylacetate (17.1 mg, 0.068 mmol) were dissolved in DMSO (800 µL) and 20 µL of 
the resulting solution were added to the mixture. Finally, didodecyldimethylammonium bromide 
(60 µL of 0.056 M a stock solution) and potassium carbonate (60 µL of 0.14 M a stock-solution) 
were added to the catalysis mixture. The resulting mixture was stirred at desired temperature for 
18 h. The reaction was extracted with Et2O (2 x 500 µL), filtered through a short silica gel plug 
and subjected to HPLC analysis. 
Daicel Chiralpak® IA column, 4.6 mm x 250 mm, particle size 5 μm. 
Mobile phase: hexane/i-propanol 95:5. 
Flow rate: 0.8 ml/min 
Room temperature 
1,3-diphenylpropenylacetate (starting material): 7.3 min 
Enantiomer (S): 12.4 min 
Enantiomer (R): 15.0 min 
trans-1,3-Diphenyl-2-propen-1-ol (hydrolysis product): 19.4 min 
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General procedure for allylic alkylation using 25% and 50% DMSO. 
 
The biotinylated ligand (8 mM stock-solution) and the Pd-precursor (6.8 mM stock solution) 
were dissolved in DMSO and mixed and stirred for 5 min at room temperature. (Strept)Avidin 
was dissolved in water (270 µL of a 83.5 μM stock solution for 25% DMSO and 160 µL of a 141 
μM stock solution for 50% DMSO, 0.092 µmol, 1.4 eq. active sites vs. metal) and mixed in a vial 
with the Pd-complex (20 µL of the stock-solution, 0.068 µmol metal) and stirred at room 
temperature for 30 min. the volume was adjusted to 360 µL by adding DMSO. Dimethylmalonate 
(43 µL, 0.34 mmol) and 1,3-diphenylpropenylacetate (17.1 mg, 0.068 mmol) were dissolved in 
dimethylsulfoxide (800 µL) and 20 µL of the resulting solution were added to the mixture. 
Finally, potassium carbonate (60 µL of 0.14 M a stock-solution) was added to the catalysis 
mixture. The resulting mixture was stirred at room temperature for 18 h. The reaction was 
extracted with Et2O (2 x 500 µL), filtered through a short silica gel plug and subjected to HPLC 
analysis. 
Daicel Chiralpak® IA column, 4.6 mm x 250 mm, particle size 5 μm. 
Mobile phase: hexane/i-propanol 95:5. 
Flow rate: 0.8 ml/min 
Room temperature 
1,3-diphenylpropenylacetate (starting material): 7.3 min 
Enantiomer (S): 12.4 min 
Enantiomer (R): 15.0 min 
trans-1,3-Diphenyl-2-propen-1-ol (hydrolysis product): 19.4 min 
 
General procedure for allylic alkylation using Cell Free Extract (CFE). 
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Catalysis with cell free extracts was performed according to the general procedure of allylic 
alkylation. Cell free extracts samples were obtained following the procedure described in the 
thesis of Dr Alessia Sardo. These samples were degassed for 2 h prior to use. 
 
General procedure for allylic substitution of cinnamyl acetate with p-cresol. 
 
The ligand (8 mM stock-solution) and the allylpalladium chloride dimer (6.8 mM stock solution) 
were dissolved in DMSO, mixed and stirred for 5 min at room temperature. (Strept)avidin was 
dissolved in water (170 µL of a 82 μM stock solution, 0.092 µmol, 1.4 eq. active sites vs. metal) 
and mixed in a vial with the Pd-complex (20 µL of the stock-solution, 0.068 µmol metal) and 
stirred at room temperature for 30 min. 170 µL of a 0.5M phosphate buffer and potassium 
carbonate (60 µL of 0.14 M a stock-solution) were added to the catalysis mixture. p-Cresol (11.1 
mg, 0.0856 mmol)  and cinnamyl acetate (6 mg, 0.0342 mmol) were each dissolved in 100 µl 
DMSO and 10 µL of the resulting solutions were added to previous mixture.. The vial was sealed 
and stirred at 50°C for 16h. After adding 10µl of the solution of internal standard (0.25 mg, 
3.42*10
-3
 mmol, 1eq), the reaction was extracted with Et2O (2 x 500 µL), filtered through a short 
silicagel plug and subjected to HPLC analysis. 
Daicel Chiralcel® OH-J column, 
Mobile phase: hexane/i-propanol 96:4. 
Flow rate: 0.8 ml/min 
Room temperature 
Starting material (cinnamyl acetate): 19.6 min 
Product: 24.3 min 
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Hydrolysis product: 27.7 min 
4-phenyl-2-butanone (standart): 17.3 min 
 
General procedure for ring closing reaction of 7. 
 
A 9 mM stock solution of the complex 3 was prepared by adding DMSO (50 µl) to an aliquot of 
the complex (0.4 mg, 0.46 µmol). A 183 mM stock solution of the substrate 7 was prepared by 
adding of N-diallyltosylamine (27 µl, 91.6 µmol) to DMSO (500 µl). In a pyrex tube was added 
0.30 mM stock solution of protein in buffer or water (100 µl), followed by the addition of the 
stock solution of the catalyst (10 µl) and the mixture was stirred for one minute. The substrate 
was added (10 µl) and the reaction flask was placed in an orbital shaker for 16 hours at 40°C. 
A 15 mM solution of phenylethanol (120 µl) was added to the reaction vial followed by MeOH 
(800 µl). The reaction solution was transferred to an eppendorf and centrifuged at 14000 rpm for 
2 minutes. The supernatant (800 µl) was added to an HPLC vial and water (800 µl) was added. 
The sample was injected in HPLC reverse phase to determine the conversion. 
Column: XDB 150 x 4.6 x 5 µl with guard column, 3 µl. 
Method: volume injected: 6 µl, at 5 min 10% CH3CN, at 15 min 90% CH3CN, at 20 min 90% 
CH3CN, at 25 min 10% CH3CN, at 30 min 10% CH3CN. 
phenylethanol: 10.690 min 
Product: 13.534 min 
N-tosyldiallylamine: 15.339 min 
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4.4 Measurements and analysis protocols. 
 
CD and UV-vis titration. 
 
Avidin (8 µM initial concentration in Tris-HCl buffer pH = 7, 2.4ml, 19.2 nmol) was charged 
with a large excess of HABA solution (9.6 mM stock solution in Tris-HCl buffer pH = 7, 50 eq 
relative to the tetramer). Aliquots of Biot-HG solution (0.96 mM in MeOH) were added to 
HABA ⊂ Avidin in 0.25 eq steps (5 µL per step, up to 7 eq) relative to the tetramer. The UV-vis 
measurement (200 - 700 nm) and the CD measurement (450 – 600 nm, band width 1 nm, 30 
nm/min, 3 accumulations) were recorded after stirring (5 min with a magnetic bar at room 
temperature). 
Streptavidin (8 µM initial concentration in 0.5 M MgCl2 in Tris-HCl buffer pH = 7 , 2.4 ml, 19.2 
nmol) were loaded with a large excess of HABA solution (9.6 mM stock solution in 0.5 M MgCl2 
in Tris-HCl buffer pH = 7, 150 eq relative to the tetramer) to ensure full saturation of the active 
site. Aliquots of Biot-mABA-HG solution (0.96 mM in MeOH) were added to HABA ⊂ 
streptavidin in 0.25 eq steps (5 µL per step, up to 7 eq) relative to the tetramer. The UV-vis 
measurement (200 - 700 nm) and the CD measurement (450 – 600 nm, band width 1 nm, 30 
nm/min, 3 accumulations) were recorded after stirring (5 min with a magnetic bar at room 
temperature). 
 
SDS-Page Electrophoresis 
12% Loading gel 
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To 5 ml nanopure H2O, 6 ml 30% acrylamide, 3.8 ml of a 1.5M Tris/HCl (pH 6.8) solution, 75 µl 
of 20% SDS, 100 µl of a 0.66M ammonium persulfate solution and 6 µl of TEMED were added. 
This solution was gently stirred for 1 min and 7 ml of this mixture were poured into the cassette. 
To prevent the gel of drying up 2 ml of ethanol were added on the top. The gel was allowed to 
polymerize for 60 min. The ethanol was removed and the top of the gel was washed with H2O. 
5% Stacking gel 
To 3.4 ml nanopure H2O, 1 ml 30% acrylamide, 0.5 ml of a 1.5M Tris/HCl (pH 6.8) solution, 30 
µl of 20% SDS, 40 µl of a 0.66M ammonium persulfate solution and 6 µl of TEMED were 
added. This solution was gently stirred for 1 min and 3 ml of this mixture were added on top of 
the loading gel. A comb was carefully placed into the stacking gel. After the gel was allowed to 
polymerize for 60 min. the comb was removed slowly. The gels were placed into the tank and the 
inner and outer reservoirs were filled up with 1X SDS Buffer.  
Sample preparation 
20 µl of the sample, 10 µl of a 3X loading buffer and 1 µl of B4F were placed in an eppendorf 
tube. The solution was gently mixed with the pipette. 10 µl of this solution were loaded on the 
gel. After separation over night at 200V, the B4F signals were detected under a UV lamp. The gel 
was then stained with a Coomassie blue solution for one day and destained over 8h.  
3X Loading Buffer 
3 ml of a 1M Tris/HCl (pH 6.8) solution was added to 20 ml nanopure H2O, followed by 1 mg 
bromophenol blue, 1.5 ml glycerol and 0.6 g of SDS. The mixture was stirred and stored at -
20°C. 
SDS Buffer 
126 
 
A 5X SDS buffer solution was obtained by dissolving 15.1 g Tris-Base, 72.0 g glycine, 5.0 g 
SDS powder in 1 l nanopure H2O. This solution was stored in the fridge. The solution was diluted 
5 times to achieve a 1X SDS Buffer before use.  
Staining solution 
Coomassie Blue (0.25 g) was dissolved in a mixture of 1 l nanopure H2O, 500 ml methanol and 
75 ml glacial acetic acid. The solution was stored at room temperature and protected from light. 
Destaining solution 
The destaining solution consists of a mixture of 810 ml nanopure H2O, 70 ml glacial acetic acid 
and 120 ml methanol. 
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